Number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	O
and	O
their	O
sensitivity	O
to	O
hormone	O
action	O
.	O
The	O
study	O
demonstrated	O
a	O
decreased	O
level	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
hypercholesterolemic	O
subjects	O
,	O
and	O
an	O
elevated	O
level	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O
In	O
the	O
lymphocytes	O
with	O
a	O
high	O
GR	B-protein
number	O
,	O
dexamethasone	O
inhibited	O
[	O
3H	O
]	O
-thymidine	O
and	O
[	O
3H	O
]	O
-acetate	O
incorporation	O
into	O
DNA	O
and	O
cholesterol	O
,	O
respectively	O
,	O
in	O
the	O
same	O
manner	O
as	O
in	O
the	O
control	O
cells	O
.	O
On	O
the	O
other	O
hand	O
,	O
a	O
decreased	O
GR	B-protein
number	O
resulted	O
in	O
a	O
less	O
efficient	O
dexamethasone	O
inhibition	O
of	O
the	O
incorporation	O
of	O
labeled	O
compounds	O
.	O
These	O
data	O
showed	O
that	O
the	O
sensitivity	O
of	O
lymphocytes	O
to	O
glucocorticoids	O
changed	O
only	O
with	O
a	O
decrease	O
of	O
GR	B-protein
level	O
.	O
[	O
1	O
,	O
25-Dihydroxyvitamin	B-protein
D3	I-protein
receptors	I-protein
in	O
lymphocytes	O
and	O
T-	O
and	O
B-lymphocyte	O
count	O
in	O
patients	O
with	O
glomerulonephritis	O
]	O
Content	O
of	O
receptors	O
to	O
hormonal	O
form	O
of	O
vitamin	O
D3	O
,	O
1.25	O
(	O
OH	O
)	O
2D3	O
,	O
constituted	O
27.3	O
fmole/mg	O
of	O
protein	O
in	O
lymphocytes	O
of	O
peripheric	O
blood	O
of	O
children	O
with	O
glomerulonephritis	O
.	O
In	O
the	O
patients	O
concentration	O
of	O
total	O
and	O
ionized	O
form	O
of	O
Ca2+	O
was	O
decreased	O
down	O
to	O
2.04	O
mmole/L	O
and	O
1.09	O
mmole/L	O
,	O
respectively	O
,	O
while	O
an	O
increase	O
in	O
parathormone	O
(	O
PTH	O
)	O
by	O
36	O
%	O
and	O
a	O
distinct	O
decrease	O
in	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
(	O
lower	O
than	O
1.25	O
ng/ml	O
)	O
was	O
found	O
in	O
blood	O
;	O
content	O
of	O
cAMP	O
was	O
also	O
decreased	O
in	O
lymphocytes	O
by	O
33	O
%	O
.	O
At	O
the	O
same	O
time	O
,	O
total	O
content	O
of	O
T	O
lymphocytes	O
was	O
decreased	O
1.5-fold	O
in	O
peripheric	O
blood	O
.	O
Treatment	O
with	O
I-hydroxyvitamin	O
D3	O
(	O
1-1.5	O
mg	O
daily	O
,	O
within	O
4	O
weeks	O
)	O
led	O
to	O
normalization	O
of	O
total	O
and	O
ionized	O
form	O
of	O
Ca2+	O
and	O
of	O
25	O
(	O
OH	O
)	O
D	O
,	O
but	O
did	O
not	O
affect	O
the	O
PTH	O
content	O
in	O
blood	O
.	O
Concentration	O
of	O
the	O
receptors	O
to	O
1.25	O
(	O
OH	O
)	O
2D3	O
was	O
elevated	O
up	O
to	O
39.7	O
fmole/mg	O
after	O
I	O
week	O
of	O
the	O
treatment	O
,	O
whereas	O
it	O
was	O
decreased	O
to	O
the	O
initial	O
level	O
24.8	O
fmole/mg	O
within	O
4	O
weeks	O
;	O
simultaneous	O
alteration	O
in	O
the	O
cAMP	O
content	O
was	O
observed	O
in	O
lymphocytes	O
.	O
Treatment	O
with	O
1-	O
(	O
OH	O
)	O
D3	O
normalized	O
also	O
the	O
T	O
lymphocytes	O
content	O
in	O
peripheric	O
blood	O
.	O
The	O
data	O
obtained	O
suggest	O
that	O
under	O
conditions	O
of	O
glomerulonephritis	O
only	O
high	O
content	O
of	O
receptors	O
to	O
1.25	O
(	O
OH	O
)	O
2D3	O
in	O
lymphocytes	O
enabled	O
to	O
perform	O
the	O
cell	O
response	O
to	O
the	O
hormone	O
effect	O
.	O
Tumor	O
and	O
serum	O
beta-2-microglobulin	O
expression	O
in	O
women	O
with	O
breast	O
cancer	O
.	O
To	O
investigate	O
whether	O
the	O
tumor	O
expression	O
of	O
beta-2-microglobulin	O
(	O
beta	O
2-M	O
)	O
could	O
serve	O
as	O
a	O
marker	O
of	O
tumor	O
biologic	O
behavior	O
,	O
the	O
authors	O
studied	O
specimens	O
of	O
breast	O
carcinomas	O
from	O
60	O
consecutive	O
female	O
patients	O
.	O
Presence	O
of	O
beta	O
2-M	O
was	O
analyzed	O
by	O
immunohistochemistry	O
.	O
No	O
significant	O
correlations	O
were	O
found	O
between	O
tumor	O
beta	O
2-M	O
expression	O
and	O
several	O
histologic	O
attributes	O
such	O
as	O
type	O
,	O
histologic	O
and	O
nuclear	O
grades	O
,	O
mitotic	O
index	O
,	O
necrosis	O
,	O
vascular	O
invasion	O
,	O
and	O
lymphocytic	O
infiltration	O
.	O
Likewise	O
,	O
beta	O
2-M	O
was	O
not	O
associated	O
with	O
markers	O
of	O
disease	O
extension	O
such	O
as	O
TNM	O
,	O
(	O
UICC	O
,	O
classification	O
of	O
malignant	O
tumors	O
)	O
staging	O
and	O
axillary	O
lymph	O
node	O
involvement	O
or	O
with	O
estrogen	O
,	O
progesterone	O
,	O
and	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
.	O
However	O
,	O
there	O
was	O
a	O
significantly	O
positive	O
association	O
between	O
tumor	O
beta	O
2-M	O
expression	O
and	O
the	O
degree	O
of	O
lymphocytic	O
infiltration	O
in	O
the	O
tumor	O
tissue	O
.	O
Beta	O
2-M	O
serum	O
levels	O
were	O
determined	O
by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
in	O
samples	O
from	O
22	O
of	O
the	O
above	O
women	O
.	O
Although	O
some	O
of	O
the	O
highest	O
values	O
had	O
been	O
obtained	O
in	O
women	O
with	O
larger	O
(	O
T4	O
)	O
primary	O
tumors	O
,	O
the	O
authors	O
failed	O
to	O
detect	O
any	O
statistical	O
relationship	O
between	O
beta	O
2-M	O
expression	O
in	O
the	O
tumor	O
with	O
serum	O
levels	O
or	O
between	O
serum	O
beta	O
2-M	O
and	O
the	O
above	O
histologic	O
,	O
laboratory	O
,	O
and	O
clinical	B-protein
factors	I-protein
.	O
[	O
Preliminary	O
observation	O
of	O
level	O
free-form	O
E	O
receptor	O
levels	O
in	O
serum	O
of	O
normal	O
childbearing-aged	O
and	O
pregnant	O
women	O
]	O
In	O
137	O
cases	O
of	O
childbearing-aged	O
and	O
pregnant	O
women	O
,	O
free	O
form	O
E	O
receptor	O
levels	O
(	O
sE	O
)	O
in	O
serum	O
were	O
measured	O
by	O
ELISA	O
.	O
The	O
level	O
of	O
sE	O
was	O
significantly	O
decreased	O
during	O
the	O
first	O
trimester	O
,	O
slightly	O
higher	O
in	O
the	O
second	O
trimester	O
,	O
and	O
recovered	O
to	O
normal	O
in	O
the	O
third	O
trimester	O
.	O
The	O
level	O
remained	O
lower	O
in	O
29	O
PIH	O
women	O
but	O
appeared	O
higher	O
in	O
overdue	O
pregnancies	O
as	O
compared	O
with	O
the	O
normal	O
3rd	O
trimester	O
range	O
.	O
The	O
results	O
indicate	O
that	O
there	O
is	O
a	O
relationship	O
between	O
a	O
change	O
in	O
T	O
cell	O
function	O
and	O
pregnancy	O
.	O
Kappa	B-protein
B-specific	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
:	O
role	O
in	O
the	O
regulation	O
of	O
human	O
interleukin-2	O
gene	O
expression	O
.	O
Transcriptional	O
activation	O
of	O
the	O
human	O
interleukin-2	O
(	O
IL-2	B-protein
)	O
gene	O
,	O
like	O
induction	O
of	O
the	O
IL-2	B-protein
receptor	I-protein
alpha	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
gene	O
and	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
,	O
is	O
shown	O
to	O
be	O
modulated	O
by	O
a	O
kappa	O
B-like	O
enhancer	O
element	O
.	O
Mutation	O
of	O
a	O
kappa	O
B	O
core	O
sequence	O
identified	O
in	O
the	O
IL-2	O
promoter	O
(	O
-206	O
to	O
-195	O
)	O
partially	O
inhibits	O
both	O
mitogen-	O
and	O
HTLV-I	O
Tax-mediated	O
activation	O
of	O
this	O
transcription	O
unit	O
and	O
blocks	O
the	O
specific	O
binding	O
of	O
two	O
inducible	O
cellular	B-protein
factors	I-protein
.	O
These	O
kappa	B-protein
B-specific	I-protein
proteins	I-protein
(	O
80	O
to	O
90	O
and	O
50	O
to	O
55	O
kilodaltons	O
)	O
similarly	O
interact	O
with	O
the	O
functional	O
kappa	O
B	O
enhancer	O
present	O
in	O
the	O
IL-2R	O
alpha	O
promoter	O
.	O
These	O
data	O
suggest	O
that	O
these	O
kappa	B-protein
B-specific	I-protein
proteins	I-protein
have	O
a	O
role	O
in	O
the	O
coordinate	O
regulation	O
of	O
this	O
growth	O
factor-growth	O
factor	O
receptor	O
gene	O
system	O
that	O
controls	O
T	O
cell	O
proliferation	O
.	O
Novel	O
region	O
within	O
the	O
V	O
kappa	O
gene	O
promoter	O
is	O
responsible	O
for	O
tissue	O
and	O
stage-specific	O
expression	O
of	O
immunoglobulin	O
genes	O
in	O
human	O
lymphoid	O
neoplasms	O
.	O
Immunoglobulin	B-protein
gene-specific	I-protein
transacting	I-protein
factors	I-protein
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
lymphoid	O
tissue-specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O
The	O
role	O
of	O
these	O
factors	O
in	O
B-cell	O
differentiation	O
and	O
stage-specific	O
expression	O
of	O
these	O
genes	O
is	O
,	O
however	O
,	O
not	O
fully	O
understood	O
.	O
We	O
have	O
used	O
a	O
model	O
of	O
human	O
lymphoid	O
neoplasia	O
to	O
address	O
this	O
question	O
.	O
Different	O
fragments	O
of	O
unrearranged	O
human	O
variable	O
region	O
of	O
immunoglobulin	O
kappa	O
gene	O
(	O
V	O
kappa	O
)	O
were	O
used	O
for	O
cell-free	O
in	O
vitro	O
transcription	O
and	O
DNA	O
mobility	O
shift	O
assays	O
.	O
Previously	O
described	O
enhancement	O
of	O
in	O
vitro	O
transcription	O
that	O
was	O
only	O
seen	O
with	O
nuclear	O
extracts	O
derived	O
from	O
B-cell	O
neoplasms	O
corresponding	O
to	O
the	O
late	O
stages	O
of	O
B-cell	O
differentiation	O
was	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
actions	O
of	O
these	O
factor	O
(	O
s	O
)	O
on	O
the	O
DNA	O
region	O
within	O
the	O
V	O
kappa	O
gene	O
promoter	O
.	O
This	O
region	O
is	O
located	O
within	O
the	O
920	O
bp	O
fragment	O
located	O
210	O
bp	O
upstream	O
from	O
the	O
coding	O
region	O
and	O
this	O
fragment	O
represents	O
a	O
possible	O
novel	O
DNA	O
region	O
,	O
which	O
plays	O
a	O
role	O
in	O
the	O
stage-	O
and	O
tissue-specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O
[	O
Determination	O
of	O
the	O
sensitivity	O
to	O
glucocorticoids	O
in	O
vitro	O
]	O
A	O
modified	O
method	O
for	O
the	O
determination	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	O
lymphocytes	O
is	O
suggested	O
.	O
The	O
principal	O
distinction	O
of	O
the	O
method	O
is	O
standardization	O
by	O
the	O
lymphocyte	O
count	O
in	O
a	O
sample	O
(	O
1	O
mln	O
)	O
and	O
the	O
labeled	O
hormone	O
concentration	O
.	O
The	O
modification	O
saves	O
time	O
and	O
money	O
,	O
limits	O
the	O
range	O
of	O
the	O
data	O
variations	O
,	O
and	O
makes	O
use	O
of	O
a	O
lesser	O
volume	O
of	O
blood	O
.	O
Examinations	O
of	O
70	O
children	O
aged	O
4	O
to	O
15	O
suffering	O
from	O
the	O
nephrotic	O
form	O
of	O
glomerulonephritis	O
have	O
made	O
it	O
possible	O
to	O
distinguish	O
two	O
groups	O
of	O
patients	O
:	O
with	O
relatively	O
high	O
values	O
of	O
specific	O
binding	O
X	O
=	O
6820.1	O
+/-	O
530.0	O
(	O
n	O
=	O
30	O
,	O
p	O
=	O
0.95	O
,	O
t	O
=	O
2.04	O
)	O
,	O
this	O
corresponding	O
to	O
a	O
clinical	O
form	O
of	O
hormone	O
-sensitive	O
glomerulonephritis	O
,	O
and	O
with	O
relatively	O
low	O
values	O
of	O
specific	O
binding	O
X	O
=	O
1815.2	O
+/-	O
302.8	O
(	O
n	O
=	O
40	O
,	O
p	O
=	O
0.95	O
,	O
t	O
=	O
1.96	O
)	O
,	O
that	O
corresponds	O
to	O
hormone	O
-resistant	O
glomerulonephritis	O
.	O
Dynamic	O
studies	O
have	O
not	O
shown	O
any	O
statistically	O
significant	O
changes	O
in	O
the	O
specific	O
binding	O
values	O
.	O
These	O
results	O
permit	O
regarding	O
the	O
specific	O
binding	O
value	O
as	O
a	O
prognostic	O
criterion	O
in	O
the	O
assessment	O
of	O
corticosteroid	O
therapy	O
;	O
this	O
allows	O
a	O
wide	O
employment	O
of	O
the	O
described	O
method	O
in	O
practical	O
nephrology	O
.	O
Octamer-binding	B-protein
proteins	I-protein
from	O
B	O
or	O
HeLa	O
cells	O
stimulate	O
transcription	O
of	O
the	O
immunoglobulin	O
heavy-chain	O
promoter	O
in	O
vitro	O
.	O
The	O
B-cell	O
-type	O
specificity	O
of	O
the	O
immunoglobulin	O
(	O
Ig	O
)	O
heavy-chain	O
and	O
light-chain	O
promoters	O
is	O
mediated	O
by	O
an	O
octanucleotide	O
(	O
OCTA	O
)	O
element	O
,	O
ATGCAAAT	O
,	O
that	O
is	O
also	O
a	O
functional	O
component	O
of	O
other	O
RNA	O
polymerase	O
II	O
promoters	O
,	O
such	O
as	O
snRNA	O
and	O
histone	O
H2B	O
promoters	O
.	O
Two	O
nuclear	B-protein
proteins	I-protein
that	O
bind	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
the	O
OCTA	O
element	O
have	O
been	O
identified	O
.	O
NF-A1	B-protein
is	O
present	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
whereas	O
the	O
presence	O
of	O
NF-A2	B-protein
is	O
essentially	O
confined	O
to	O
B	O
cells	O
,	O
leading	O
to	O
the	O
hypothesis	O
that	O
NF-A2	B-protein
activates	O
cell-type-specific	O
transcription	O
of	O
the	O
Ig	O
promoter	O
and	O
NF-A1	O
mediates	O
the	O
other	O
responses	O
of	O
the	O
OCTA	O
element	O
.	O
Extracts	O
of	O
the	O
B-cell	O
line	O
,	O
BJA-B	O
,	O
contain	O
high	O
levels	O
of	O
NF-A2	B-protein
and	O
specifically	O
transcribe	O
Ig	O
promoters	O
.	O
In	O
contrast	O
,	O
extracts	O
from	O
HeLa	O
cells	O
transcribed	O
the	O
Ig	O
promoter	O
poorly	O
.	O
Surprisingly	O
,	O
addition	O
of	O
either	O
affinity-enriched	O
NF-A2	O
or	O
NF-A1	O
to	O
either	O
a	O
HeLa	O
extract	O
or	O
a	O
partially	O
purified	O
reaction	O
system	O
specifically	O
stimulates	O
the	O
Ig	O
promoter	O
.	O
This	O
suggests	O
that	O
the	O
constitutive	O
OCTA-binding	O
factor	O
NF-A1	O
can	O
activate	O
transcription	O
of	O
the	O
Ig	O
promoter	O
and	O
that	O
B-cell	O
-specific	O
transcription	O
of	O
this	O
promoter	O
,	O
at	O
least	O
in	O
vitro	O
,	O
is	O
partially	O
due	O
to	O
a	O
quantitative	O
difference	O
in	O
the	O
amount	O
of	O
OCTA-binding	B-protein
protein	I-protein
.	O
Because	O
NF-A1	O
can	O
stimulate	O
Ig	O
transcription	O
,	O
the	O
inability	O
of	O
this	O
factor	O
to	O
activate	O
in	O
vivo	O
the	O
Ig	O
promoter	O
to	O
the	O
same	O
degree	O
as	O
the	O
snRNA	O
promoters	O
probably	O
reflects	O
a	O
difference	O
in	O
the	O
context	O
of	O
the	O
OCTA	O
element	O
in	O
these	O
two	O
types	O
of	O
promoters	O
.	O
Identification	O
of	O
a	O
putative	B-protein
regulator	I-protein
of	O
early	O
T	O
cell	O
activation	O
genes	O
.	O
Molecules	O
involved	O
in	O
the	O
antigen	O
receptor-dependent	O
regulation	O
of	O
early	O
T	O
cell	O
activation	O
genes	O
were	O
investigated	O
with	O
the	O
use	O
of	O
functional	O
sequences	O
of	O
the	O
T	O
cell	O
activation-specific	O
enhancer	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O
One	O
of	O
these	O
sequences	O
forms	O
a	O
protein	B-protein
complex	I-protein
,	O
NFAT-1	B-protein
,	O
specifically	O
with	O
nuclear	O
extracts	O
of	O
activated	O
T	O
cells	O
.	O
This	O
complex	O
appeared	O
10	O
to	O
25	O
minutes	O
before	O
the	O
activation	O
of	O
the	O
IL-2	O
gene	O
.	O
Studies	O
with	O
inhibitors	O
of	O
protein	O
synthesis	O
indicated	O
that	O
the	O
time	O
of	O
synthesis	O
of	O
the	O
activator	O
of	O
the	O
IL-2	O
gene	O
in	O
Jurkat	O
T	O
cells	O
corresponds	O
to	O
the	O
time	O
of	O
appearance	O
of	O
NFAT-1	B-protein
.	O
NFAT-1	B-protein
,	O
or	O
a	O
very	O
similar	O
protein	O
,	O
bound	O
functional	O
sequences	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
;	O
the	O
LTR	O
of	O
this	O
virus	O
is	O
known	O
to	O
be	O
stimulated	O
during	O
early	O
T	O
cell	O
activation	O
.	O
The	O
binding	O
site	O
for	O
this	O
complex	O
activated	O
a	O
linked	O
promoter	O
after	O
transfection	O
into	O
antigen	O
receptor-activated	O
T	O
cells	O
but	O
not	O
other	O
cell	O
types	O
.	O
These	O
characteristics	O
suggest	O
that	O
NFAT-1	O
transmits	O
signals	O
initiated	O
at	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O
Characterization	O
of	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
in	O
human	O
IM-9	O
lymphocytes	O
.	O
Although	O
putatively	O
identified	O
more	O
than	O
10	O
years	O
ago	O
,	O
thyroid	O
hormone	B-protein
receptors	I-protein
in	O
human	O
tissues	O
remain	O
poorly	O
characterized	O
.	O
As	O
a	O
first	O
step	O
towards	O
understanding	O
the	O
mechanism	O
of	O
thyroid	O
hormone	O
action	O
in	O
man	O
we	O
have	O
characterized	O
T3	O
binding	O
sites	O
in	O
nuclei	O
of	O
the	O
human	O
lymphoblastoid	O
line	O
,	O
IM-9	O
cells	O
.	O
In	O
whole	O
cell	O
experiments	O
at	O
37	O
degrees	O
C	O
,	O
nuclear	O
binding	O
of	O
[	O
125I	O
]	O
T3	O
was	O
saturable	O
(	O
Kd	O
34	O
+/-	O
6	O
pmol/l	O
)	O
and	O
of	O
finite	O
capacity	O
(	O
approximately	O
equal	O
to	O
350	O
sites/cell	O
)	O
.	O
The	O
binding	O
sites	O
were	O
extracted	O
from	O
a	O
nuclear	O
pellet	O
by	O
treatment	O
with	O
0.4	O
mol/l	O
KCl	O
and	O
sonication	O
.	O
Separation	O
of	O
bound	O
from	O
free	O
[	O
125I	O
]	O
T3	O
in	O
the	O
extracts	O
was	O
achieved	O
using	O
the	O
calcium	O
phosphate	O
matrix	O
,	O
hydroxyapatite	O
at	O
a	O
concentration	O
of	O
0.3	O
ml	O
of	O
a	O
150	O
g/l	O
slurry	O
.	O
Rectilinear	O
Scatchard	O
plots	O
were	O
obtained	O
only	O
when	O
the	O
hydroxyapatite	O
was	O
washed	O
with	O
a	O
buffer	O
containing	O
0.5	O
%	O
Triton	O
X-100	O
.	O
Under	O
these	O
conditions	O
T3	O
binding	O
sites	O
in	O
the	O
nuclear	O
extracts	O
were	O
present	O
at	O
a	O
concentration	O
of	O
22.4	O
+/-	O
8.6	O
fmol/mg	O
protein	O
and	O
showed	O
an	O
affinity	O
of	O
(	O
Kd	O
,	O
room	O
temperature	O
)	O
140	O
+/-	O
10	O
pmol/l	O
.	O
The	O
same	O
assay	O
system	O
was	O
used	O
to	O
determine	O
the	O
hierarchy	O
of	O
affinities	O
for	O
a	O
range	O
of	O
natural	O
and	O
synthetic	O
analogues	O
.	O
Calling	O
T3	O
100	O
,	O
the	O
order	O
of	O
potencies	O
observed	O
was	O
:	O
Triac	O
,	O
500	O
;	O
3	O
,	O
5-diiodo-3'-isopropylthyronine	O
,	O
89	O
;	O
T4	O
,	O
32	O
;	O
3	O
,	O
5-dimethyl-3'isopropylthyronine	O
2	O
;	O
3	O
,	O
5-T2	O
,	O
0.7	O
,	O
rT3	O
,	O
0.4	O
;	O
3'5'-T2	O
,	O
less	O
than	O
0.01	O
.	O
These	O
results	O
suggest	O
that	O
the	O
T3	O
binding	O
sites	O
present	O
in	O
human	O
IM-9	O
lymphocyte	O
nuclei	O
and	O
extracts	O
thereof	O
are	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
.	O
These	O
cells	O
may	O
be	O
a	O
useful	O
tool	O
to	O
increase	O
our	O
understanding	O
of	O
human	B-protein
T3	I-protein
receptors	I-protein
Definition	O
of	O
T-cell	B-protein
specific	I-protein
DNA-binding	I-protein
factors	I-protein
that	O
interact	O
with	O
a	O
3'-silencer	O
in	O
the	O
CD4+	O
T-cell	O
gene	O
Rpt-1	O
.	O
Analysis	O
of	O
the	O
region	O
3	O
'	O
to	O
the	O
CD4+	O
T-cell	O
gene	O
Rpt-1	O
(	O
encoding	O
regulatory	B-protein
protein	I-protein
T-lymphocyte	I-protein
1	I-protein
)	O
led	O
to	O
the	O
definition	O
of	O
a	O
silencer	O
element	O
that	O
inhibits	O
heterologous	O
gene	O
expression	O
in	O
certain	O
CD4+	O
T-cell	O
lines	O
but	O
not	O
in	O
B-cell	O
or	O
non-lymphoid	O
cell	O
lines	O
.	O
Functional	O
silencer	O
activity	O
in	O
vivo	O
was	O
associated	O
with	O
the	O
presence	O
of	O
a	O
specific	O
silencer-DNA-protein	O
complex	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
T-cell	O
extracts	O
.	O
Formation	O
of	O
this	O
complex	O
was	O
selectively	O
inhibited	O
by	O
the	O
region	O
in	O
HIV-1	O
containing	O
a	O
silencer	O
element	O
.	O
We	O
discuss	O
the	O
possibility	O
that	O
DNA-binding	B-protein
factors	I-protein
may	O
coregulate	O
HIV-1	O
and	O
Rpt-1	O
gene	O
expression	O
through	O
a	O
common	O
transcriptional	O
silencer	O
element	O
.	O
Congenital	O
immunodeficiencies	O
associated	O
with	O
absence	O
of	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
on	O
lymphocytes	O
result	O
from	O
distinct	O
mutations	O
in	O
trans-acting	B-protein
factors	I-protein
.	O
Coordinate	O
regulation	O
of	O
HLA	O
class	O
II	O
gene	O
expression	O
during	O
development	O
and	O
coinduction	O
of	O
class	O
II	O
genes	O
by	O
soluble	B-protein
factors	I-protein
suggests	O
that	O
common	O
trans-acting	B-protein
factor	I-protein
(	O
s	O
)	O
control	O
expression	O
of	O
these	O
genes	O
.	O
In	O
B-lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
two	O
independent	O
class	O
II-deficient	O
bare	O
lymphocyte	O
syndrome	O
patients	O
,	O
we	O
observed	O
a	O
drastic	O
decrease	O
in	O
transcription	O
rates	O
of	O
the	O
class	O
II	O
genes	O
.	O
When	O
these	O
cell	O
lines	O
are	O
fused	O
,	O
class	O
II	O
genes	O
are	O
reexpressed	O
,	O
indicating	O
that	O
immunodeficiencies	O
in	O
bare	O
lymphocyte	O
syndrome	O
patients	O
are	O
the	O
result	O
of	O
two	O
distinct	O
mutations	O
.	O
Further	O
studies	O
show	O
that	O
genes	O
governing	O
the	O
expression	O
of	O
class	B-protein
II	I-protein
antigens	I-protein
fall	O
into	O
at	O
least	O
three	O
complementation	O
groups	O
;	O
two	O
of	O
these	O
were	O
previously	O
unidentified	O
in	O
mutant	O
cell	O
lines	O
generated	O
in	O
vitro	O
.	O
In	O
addition	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
discrete	O
complexes	O
,	O
NFX1.1	O
and	O
NFX1.2	O
,	O
that	O
bind	O
to	O
the	O
DRA	O
X	O
consensus	O
element	O
.	O
Though	O
the	O
mutation	O
in	O
at	O
least	O
one	O
mutant	O
line	O
generated	O
in	O
vitro	O
(	O
RJ2.2.5	O
)	O
affects	O
products	O
functioning	O
via	O
interaction	O
with	O
the	O
X	O
box	O
,	O
clear	O
alterations	O
in	O
either	O
NFX1.1	O
or	O
NFX1.2	B-protein
are	O
not	O
found	O
in	O
any	O
of	O
the	O
mutant	O
cell	O
lines	O
.	O
In	O
vivo	O
responsiveness	O
to	O
glucocorticoid	O
correlated	O
with	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
peripheral	O
blood	O
leukocytes	O
in	O
normal	O
humans	O
.	O
Dexamethasone	O
loading	O
tests	O
(	O
0.1	O
mg	O
dexamethasone/kg	O
,	O
iv	O
)	O
were	O
performed	O
in	O
18	O
normal	O
males	O
to	O
evaluate	O
the	O
individual	O
responsiveness	O
to	O
glucocorticoid	O
.	O
There	O
were	O
inter-individual	O
differences	O
in	O
increase	O
in	O
peripheral	O
blood	O
polymorphonuclear	O
leukocyte	O
count	O
,	O
decrease	O
in	O
peripheral	O
blood	O
lymphocyte	O
count	O
,	O
and	O
increase	O
in	O
plasma	O
free	O
fatty	O
acids	O
levels	O
after	O
dexamethasone	O
injection	O
.	O
In	O
addition	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
maximum	O
increase	O
in	O
polymorphonuclear	O
leukocytes	O
and	O
the	O
maximum	O
decrease	O
in	O
lymphocytes	O
(	O
r	O
=	O
0.7514	O
,	O
p	O
less	O
than	O
0.0003	O
)	O
.	O
Simultaneous	O
measurements	O
of	O
glucocorticoid	B-protein
receptor	I-protein
content	O
by	O
whole-cell	O
assay	O
revealed	O
that	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
polymorphonuclear	O
leukocytes	O
linearly	O
correlated	O
with	O
that	O
in	O
the	O
corresponding	O
lymphocytes	O
(	O
r	O
=	O
0.9482	O
,	O
p	O
less	O
than	O
0.0001	O
)	O
.	O
There	O
were	O
also	O
significant	O
correlations	O
between	O
the	O
maximum	O
increase	O
in	O
polymorphonuclear	O
leukocytes	O
and	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
polymorphonuclear	O
leukocytes	O
(	O
r	O
=	O
0.7239	O
,	O
p	O
less	O
than	O
0.0007	O
)	O
,	O
and	O
between	O
the	O
maximum	O
decrease	O
in	O
lymphocytes	O
and	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
lymphocytes	O
(	O
r	O
=	O
0.7703	O
,	O
p	O
less	O
than	O
0.0002	O
)	O
.	O
These	O
results	O
suggest	O
that	O
individual	O
differences	O
are	O
preserved	O
both	O
in	O
glucocorticoid	O
responsiveness	O
and	O
in	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
peripheral	O
blood	O
leukocytes	O
in	O
normal	O
humans	O
.	O
Estradiol	B-protein
receptors	I-protein
in	O
the	O
cytosol	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
hepatitis	O
B	O
virus	O
carriers	O
treated	O
with	O
interferon-alpha	B-protein
.	O
Estradiol	B-protein
receptors	I-protein
in	O
the	O
cytosol	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
the	O
effects	O
of	O
interferon-alpha	O
(	O
IFN-alpha	B-protein
)	O
on	O
estradiol	O
receptors	O
were	O
studied	O
in	O
asymptomatic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
carriers	O
,	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
and	O
normal	O
controls	O
.	O
The	O
level	O
of	O
estradiol	B-protein
receptors	I-protein
in	O
the	O
cytosol	O
of	O
mononuclear	O
cells	O
was	O
significantly	O
lower	O
in	O
asymptomatic	O
HBV	O
carriers	O
and	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
,	O
compared	O
to	O
normal	O
controls	O
.	O
This	O
low	O
level	O
of	O
cytosol	B-protein
estradiol	I-protein
receptors	I-protein
in	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
was	O
increased	O
by	O
the	O
administration	O
of	O
IFN-alpha	B-protein
.	O
In	O
addition	O
,	O
when	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
were	O
incubated	O
with	O
IFN-alpha	B-protein
in	O
vitro	O
,	O
the	O
level	O
of	O
cytosol	B-protein
estradiol	I-protein
receptors	I-protein
also	O
increased	O
by	O
increasing	O
the	O
concentration	O
of	O
IFN-alpha	B-protein
.	O
We	O
previously	O
reported	O
that	O
the	O
response	O
of	O
mononuclear	O
cells	O
to	O
estrogen	O
is	O
impaired	O
in	O
HBV	O
carriers	O
,	O
and	O
our	O
present	O
results	O
suggested	O
that	O
this	O
may	O
be	O
due	O
to	O
the	O
low	O
level	O
of	O
estradiol	B-protein
receptors	I-protein
in	O
the	O
cytosol	O
of	O
mononuclear	O
cells	O
.	O
Association	O
of	O
increased	O
lytic	O
effector	O
cell	O
function	O
with	O
high	O
estrogen	B-protein
receptor	I-protein
levels	O
in	O
tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
.	O
Tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
were	O
assayed	O
for	O
their	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
and	O
for	O
the	O
function	O
of	O
activated	O
cytotoxic	O
T-cells	O
,	O
as	O
assessed	O
by	O
lectin-dependent	O
cellular	O
cytotoxicity	O
(	O
LDCC	O
)	O
.	O
Tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
had	O
a	O
significant	O
increase	O
in	O
NK	O
activity	O
and	O
in	O
LDCC	O
,	O
as	O
compared	O
with	O
healthy	O
control	O
individuals	O
.	O
Although	O
the	O
enhanced	O
NK	O
cell	O
activity	O
and	O
LDCC	O
were	O
closely	O
associated	O
with	O
high	O
levels	O
(	O
greater	O
than	O
31	O
fmol/mg	O
)	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
content	O
in	O
the	O
primary	O
tumor	O
,	O
no	O
other	O
clinical	O
or	O
histologic	O
correlation	O
between	O
the	O
increase	O
in	O
either	O
parameter	O
of	O
cytotoxic	O
effector	O
cell	O
function	O
could	O
be	O
found	O
.	O
Thus	O
,	O
ER	B-protein
levels	O
greater	O
than	O
31	O
fmol/mg	O
might	O
be	O
associated	O
with	O
increased	O
cytotoxic	O
effector	O
cell	O
function	O
in	O
tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
.	O
Properties	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
Epstein-Barr	O
virus-transformed	O
lymphocytes	O
from	O
patients	O
with	O
familial	O
cortisol	O
resistance	O
.	O
In	O
a	O
previous	O
report	O
of	O
two	O
patients	O
with	O
familial	O
glucocorticoid	O
resistance	O
due	O
to	O
reduced	O
numbers	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
,	O
we	O
have	O
shown	O
decreased	O
numbers	O
of	O
GR	B-protein
in	O
peripheral	O
mononuclear	O
cells	O
and	O
cultured	O
fibroblasts	O
but	O
normal	O
affinity	O
of	O
GR	B-protein
in	O
both	O
patients	O
.	O
In	O
this	O
study	O
,	O
peripheral	O
lymphocytes	O
from	O
these	O
patients	O
,	O
one	O
patient	O
's	O
son	O
and	O
daughter	O
,	O
and	O
normal	O
subjects	O
were	O
transformed	O
with	O
Epstein-Barr	O
virus	O
.	O
Reduced	O
numbers	O
and	O
normal	O
affinity	O
of	O
GR	B-protein
were	O
found	O
in	O
the	O
Epstein-Barr	O
virus-transformed	O
lymphocytes	O
from	O
both	O
patients	O
while	O
the	O
son	O
and	O
daughter	O
had	O
normal	O
numbers	O
and	O
affinity	O
of	O
GR	B-protein
.	O
The	O
thermal	O
stability	O
of	O
GR	B-protein
and	O
thermal	O
activation	O
of	O
cytosolic	B-protein
receptors	I-protein
in	O
both	O
patients	O
were	O
found	O
to	O
be	O
normal	O
.	O
Although	O
the	O
percentages	O
of	O
nuclear	O
bound	O
GR	B-protein
were	O
similar	O
in	O
both	O
patients	O
and	O
normal	O
controls	O
,	O
the	O
absolute	O
amounts	O
of	O
nuclear	O
bound	O
GR	B-protein
of	O
the	O
patients	O
were	O
about	O
one-half	O
that	O
of	O
normal	O
controls	O
.	O
These	O
abnormal	O
properties	O
of	O
GR	B-protein
(	O
reduced	O
numbers	O
of	O
GR	B-protein
)	O
were	O
preserved	O
in	O
the	O
transformed	O
cells	O
from	O
the	O
patients	O
.	O
Octamer	B-protein
transcription	I-protein
factors	I-protein
1	I-protein
and	O
2	O
each	O
bind	O
to	O
two	O
different	O
functional	O
elements	O
in	O
the	O
immunoglobulin	O
heavy-chain	O
promoter	O
.	O
Immunoglobulin	O
heavy-chain	O
genes	O
contain	O
two	O
conserved	O
sequence	O
elements	O
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
:	O
the	O
octamer	O
ATGCAAAT	O
and	O
the	O
heptamer	O
CTCATGA	O
.	O
Both	O
of	O
these	O
elements	O
are	O
required	O
for	O
normal	O
cell-specific	O
promoter	O
function	O
.	O
The	O
present	O
study	O
demonstrates	O
that	O
both	O
the	O
ubiquitous	O
and	O
lymphoid-cell-specific	B-protein
octamer	I-protein
transcription	I-protein
factors	I-protein
(	O
OTF-1	O
and	O
OTF-2	O
,	O
respectively	O
)	O
interact	O
specifically	O
with	O
each	O
of	O
the	O
two	O
conserved	O
sequence	O
elements	O
,	O
forming	O
either	O
homo-	O
or	O
heterodimeric	B-protein
complexes	I-protein
.	O
This	O
was	O
surprising	O
,	O
since	O
the	O
heptamer	O
and	O
octamer	O
sequence	O
motifs	O
bear	O
no	O
obvious	O
similarity	O
to	O
each	O
other	O
.	O
Binding	O
of	O
either	O
factor	O
to	O
the	O
octamer	O
element	O
occurred	O
independently	O
.	O
However	O
,	O
OTF	O
interaction	O
with	O
the	O
heptamer	O
sequence	O
appeared	O
to	O
require	O
the	O
presence	O
of	O
an	O
intact	O
octamer	O
motif	O
and	O
occurred	O
with	O
a	O
spacing	O
of	O
either	O
2	O
or	O
14	O
base	O
pairs	O
between	O
the	O
two	O
elements	O
,	O
suggesting	O
coordinate	O
binding	O
resulting	O
from	O
protein-protein	O
interactions	O
.	O
The	O
degeneracy	O
in	O
sequences	O
recognized	O
by	O
the	O
OTFs	O
may	O
be	O
important	O
in	O
widening	O
the	O
range	O
over	O
which	O
gene	O
expression	O
can	O
be	O
modulated	O
and	O
in	O
establishing	O
cell	O
type	O
specificity	O
.	O
Identification	O
of	O
a	O
novel	O
lymphoid	O
specific	O
octamer	B-protein
binding	I-protein
protein	I-protein
(	O
OTF-2B	O
)	O
by	O
proteolytic	O
clipping	O
bandshift	O
assay	O
(	O
PCBA	O
)	O
.	O
The	O
octamer	O
sequence	O
ATGCAAAT	O
is	O
found	O
in	O
the	O
promoters	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
heavy	O
and	O
light	O
chain	O
genes	O
and	O
in	O
the	O
heavy	O
chain	O
enhancer	O
and	O
is	O
a	O
major	O
determinant	O
of	O
the	O
cell	O
type	O
specific	O
expression	O
of	O
Ig	O
genes	O
in	O
B	O
cells	O
.	O
An	O
apparent	O
paradox	O
is	O
that	O
the	O
same	O
sequence	O
serves	O
as	O
an	O
upstream	O
promoter	O
or	O
enhancer	O
element	O
in	O
a	O
variety	O
of	O
housekeeping	O
genes	O
such	O
as	O
the	O
histone	B-protein
H2B	I-protein
and	O
U	O
snRNA	O
genes	O
.	O
The	O
differential	O
usage	O
of	O
this	O
regulatory	O
sequence	O
motif	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
different	O
species	O
of	O
octamer	B-protein
binding	I-protein
proteins	I-protein
.	O
One	O
species	O
of	O
100	O
kd	O
,	O
designated	O
OTF-1	O
,	O
is	O
present	O
in	O
all	O
cell	O
types	O
and	O
may	O
exert	O
its	O
activating	O
function	O
only	O
when	O
it	O
can	O
interact	O
with	O
additional	O
adjacent	O
transcription	B-protein
factors	I-protein
.	O
The	O
lymphoid	O
cell	O
specific	O
octamer	B-protein
binding	I-protein
protein	I-protein
of	O
60	O
kd	O
(	O
OTF-2A	O
)	O
specifically	O
stimulates	O
Ig	O
promoters	O
which	O
consist	O
essentially	O
of	O
a	O
TATA-box	O
and	O
an	O
octamer	O
sequence	O
upstream	O
of	O
it	O
.	O
Here	O
we	O
present	O
evidence	O
for	O
yet	O
another	O
B	O
cell	O
specific	O
octamer	B-protein
binding	I-protein
protein	I-protein
of	O
75	O
kd	O
(	O
OTF-2B	O
)	O
.	O
From	O
several	O
findings	O
,	O
including	O
the	O
absence	O
of	O
OTF-2B	O
(	O
but	O
not	O
OTF-2A	O
)	O
from	O
a	O
lymphocyte	O
line	O
that	O
can	O
not	O
respond	O
to	O
the	O
IgH	O
enhancer	O
,	O
we	O
propose	O
a	O
role	O
of	O
the	O
novel	O
octamer	O
factor	O
in	O
the	O
long	O
range	O
activation	O
by	O
the	O
IgH	O
enhancer	O
.	O
We	O
have	O
used	O
the	O
proteolytic	O
clipping	O
bandshift	O
assay	O
(	O
PCBA	O
)	O
technique	O
to	O
distinguish	O
the	O
three	O
different	O
forms	O
found	O
in	O
B	O
cells	O
.	O
This	O
analysis	O
indicates	O
that	O
the	O
75	O
kd-species	O
OTF-2B	O
is	O
closely	O
related	O
to	O
the	O
60	O
kd	O
species	O
OTF-2A	O
.	O
Inhibition	O
of	O
interleukin	B-protein
2	I-protein
-induced	O
proliferation	O
of	O
cloned	O
murine	O
T	O
cells	O
by	O
glucocorticoids	O
.	O
Possible	O
involvement	O
of	O
an	O
inhibitory	O
protein	O
.	O
The	O
ability	O
of	O
glucocorticoids	O
to	O
inhibit	O
interleukin	B-protein
2	I-protein
(	I-protein
IL	I-protein
2	I-protein
)	I-protein
-induced	O
T	O
cell	O
proliferation	O
in	O
two	O
cytotoxic	O
T	O
cell	O
(	O
CTL	O
)	O
clones	O
has	O
been	O
studied	O
.	O
A	O
complete	O
inhibition	O
of	O
DNA	O
synthesis	O
by	O
dexamethasone	O
(	O
Dx	O
)	O
could	O
be	O
observed	O
when	O
IL	O
2-depleted	O
cultures	O
of	O
CTL	O
were	O
either	O
incubated	O
for	O
6	O
h	O
with	O
the	O
hormone	O
prior	O
to	O
the	O
addition	O
of	O
IL	B-protein
2	I-protein
or	O
treated	O
simultaneously	O
with	O
Dx	O
and	O
a	O
low	O
concentration	O
of	O
IL	B-protein
2	I-protein
.	O
No	O
significant	O
reduction	O
in	O
the	O
number	O
and	O
affinity	O
of	O
IL	B-protein
2	I-protein
receptors	I-protein
was	O
seen	O
after	O
6	O
h	O
incubation	O
with	O
Dx	O
.	O
The	O
order	O
of	O
potency	O
observed	O
with	O
the	O
different	O
steroids	O
indicated	O
that	O
this	O
inhibitory	O
effect	O
was	O
mediated	O
through	O
binding	O
to	O
a	O
specific	O
glucocorticoid	B-protein
receptor	I-protein
.	O
The	O
action	O
of	O
these	O
hormones	O
possibly	O
involves	O
the	O
synthesis	O
of	O
an	O
inhibitory	O
protein	O
(	O
s	O
)	O
,	O
since	O
the	O
presence	O
of	O
cycloheximide	O
during	O
the	O
incubation	O
with	O
Dx	O
prevented	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O
Furthermore	O
,	O
supernatant	O
from	O
Dx-treated	O
CTL	O
contained	O
a	O
nondialyzable	B-protein
factor	I-protein
which	O
inhibited	O
DNA	O
synthesis	O
and	O
cell	O
growth	O
of	O
CTL	O
clones	O
induced	O
by	O
IL	B-protein
2	I-protein
.	O
Blocking	O
of	O
IL	B-protein
2	I-protein
synthesis	I-protein
and	I-protein
IL	I-protein
2	I-protein
receptor	I-protein
formation	O
have	O
been	O
proposed	O
as	O
one	O
of	O
the	O
major	O
mechanisms	O
of	O
glucocorticoid-induced	O
immunosuppression	O
.	O
Our	O
results	O
indicate	O
that	O
these	O
hormones	O
may	O
also	O
affect	O
T	O
cell	O
proliferation	O
by	O
inhibiting	O
IL	O
2	O
activity	O
.	O
Identification	O
and	O
purification	O
of	O
a	O
human	B-protein
immunoglobulin-enhancer-binding	I-protein
protein	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
that	O
activates	O
transcription	O
from	O
a	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
promoter	O
in	O
vitro	O
.	O
The	O
enhancer-binding	O
factor	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
is	O
found	O
only	O
in	O
cells	O
that	O
transcribe	O
immunoglobulin	O
light	O
chain	O
genes	O
,	O
has	O
been	O
purified	O
from	O
nuclear	O
extracts	O
of	O
Namalwa	O
cells	O
(	O
human	O
Burkitt	O
lymphoma	O
cells	O
)	O
by	O
sequence-specific	O
DNA	O
affinity	O
chromatography	O
.	O
The	O
purified	B-protein
NF-kappa	I-protein
B	I-protein
has	O
been	O
identified	O
as	O
a	O
51-kDa	O
polypeptide	O
by	O
UV-crosslinking	O
analysis	O
.	O
``	O
Footprint	O
''	O
and	O
methylation-interference	O
analyses	O
have	O
shown	O
that	O
purified	O
NF-kappa	B-protein
B	I-protein
has	O
a	O
binding	O
activity	O
specific	O
for	O
the	O
kappa	B-protein
light	I-protein
chain	I-protein
enhancer	I-protein
sequence	I-protein
.	O
The	O
purified	B-protein
factor	I-protein
activated	O
in	O
vitro	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
I	O
promoter	O
by	O
binding	O
to	O
an	O
upstream	O
NF-kappa	B-protein
B-binding	I-protein
site	I-protein
Lymphocyte	I-protein
glucocorticoid	I-protein
receptor	I-protein
binding	O
in	O
depression	O
:	O
normal	O
values	O
following	O
recovery	O
.	O
The	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
in	O
lymphocytes	O
and	O
plasma	O
cortisol	O
concentrations	O
were	O
measured	O
in	O
20	O
patients	O
who	O
had	O
recovered	O
from	O
major	O
depressive	O
disorder	O
and	O
20	O
healthy	O
control	O
subjects	O
.	O
The	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
in	O
lymphocytes	O
from	O
the	O
recovered	O
depressed	O
group	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
control	O
group	O
.	O
Although	O
the	O
mean	O
plasma	O
cortisol	O
concentration	O
in	O
recovered	O
depressives	O
was	O
higher	O
than	O
in	O
control	O
subjects	O
,	O
the	O
difference	O
only	O
just	O
reached	O
significance	O
.	O
This	O
study	O
shows	O
that	O
the	O
reduction	O
in	O
glucocorticoid	B-protein
receptor	I-protein
numbers	O
which	O
occurs	O
during	O
acute	O
depressive	O
illness	O
does	O
not	O
persist	O
on	O
recovery	O
and	O
is	O
,	O
therefore	O
,	O
state-dependent	O
.	O
Identification	O
and	O
purification	O
of	O
a	O
human	O
lymphoid-specific	O
octamer-binding	O
protein	O
(	O
OTF-2	O
)	O
that	O
activates	O
transcription	O
of	O
an	O
immunoglobulin	O
promoter	O
in	O
vitro	O
.	O
The	O
octamer	O
sequence	O
5'-ATGCAAAT	O
,	O
in	O
either	O
orientation	O
,	O
serves	O
as	O
an	O
upstream	O
element	O
in	O
a	O
variety	O
of	O
promoters	O
and	O
also	O
occurs	O
as	O
a	O
modular	O
enhancer	O
element	O
.	O
It	O
is	O
of	O
particular	O
interest	O
in	O
immunoglobulin	O
genes	O
since	O
it	O
is	O
found	O
in	O
the	O
upstream	O
regions	O
of	O
all	O
heavy	O
and	O
light	O
chain	O
promoters	O
and	O
in	O
the	O
heavy	O
chain	O
enhancer	O
,	O
both	O
of	O
which	O
are	O
known	O
to	O
be	O
necessary	O
for	O
cell-specific	O
expression	O
.	O
We	O
report	O
here	O
the	O
chromatographic	O
separation	O
of	O
ubiquitous	O
and	O
B	B-protein
cell-specific	I-protein
octamer-binding	I-protein
proteins	I-protein
.	O
The	O
B	O
cell	O
factor	O
was	O
purified	O
to	O
homogeneity	O
using	O
affinity	O
chromatography	O
and	O
consists	O
of	O
three	O
peptides	O
of	O
62	O
,	O
61	O
,	O
and	O
58.5	O
+/-	O
1.5	O
kd	O
.	O
Each	O
of	O
the	O
polypeptides	O
was	O
renatured	O
after	O
SDS-PAGE	O
and	O
shown	O
to	O
bind	O
to	O
the	O
octamer	O
sequence	O
.	O
The	O
specific	O
DNA	O
binding	O
activity	O
of	O
the	O
pure	O
B	B-protein
cell-specific	I-protein
factor	I-protein
was	O
indistinguishable	O
from	O
that	O
of	O
the	O
affinity-purified	O
ubiquitous	O
factor	O
.	O
This	O
B	B-protein
cell-specific	I-protein
octamer-binding	I-protein
factor	I-protein
,	O
in	O
pure	O
form	O
,	O
activated	O
transcription	O
from	O
a	O
kappa	O
light	O
chain	O
promoter	O
in	O
vitro	O
,	O
thus	O
demonstrating	O
that	O
it	O
is	O
indeed	O
a	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
for	O
this	O
gene	O
.	O
In	O
addition	O
to	O
the	O
ubiquitous	O
and	O
B	B-protein
cell-specific	I-protein
octamer-binding	I-protein
factors	I-protein
,	O
we	O
identified	O
several	O
additional	O
proteins	O
,	O
one	O
of	O
which	O
is	O
B	O
cell	O
-specific	O
,	O
that	O
interact	O
with	O
the	O
kappa	O
promoter	O
.	O
Decreased	O
deoxyribonucleic	O
acid	O
binding	O
of	O
glucocorticoid-receptor	B-protein
complex	I-protein
in	O
cultured	O
skin	O
fibroblasts	O
from	O
a	O
patient	O
with	O
the	O
glucocorticoid	O
resistance	O
syndrome	O
.	O
A	O
patient	O
with	O
the	O
syndrome	O
of	O
glucocorticoid	O
resistance	O
was	O
studied	O
.	O
A	O
27-yr-old	O
woman	O
initially	O
was	O
diagnosed	O
as	O
having	O
Cushing	O
's	O
disease	O
,	O
based	O
on	O
the	O
findings	O
of	O
high	O
plasma	O
ACTH	O
and	O
serum	O
cortisol	O
levels	O
,	O
increased	O
urinary	O
cortisol	O
secretion	O
,	O
resistance	O
to	O
adrenal	O
suppression	O
with	O
dexamethasone	O
,	O
and	O
bilateral	O
adrenal	O
hyperplasia	O
by	O
computed	O
tomography	O
and	O
scintigraphy	O
of	O
the	O
adrenal	O
glands	O
.	O
However	O
,	O
she	O
had	O
no	O
signs	O
or	O
symptoms	O
of	O
Cushing	O
's	O
syndrome	O
.	O
During	O
a	O
5-yr	O
follow-up	O
,	O
no	O
clinical	O
abnormalities	O
developed	O
,	O
although	O
hypercortisolism	O
persisted	O
.	O
End-organ	O
resistance	O
to	O
cortisol	O
was	O
suspected	O
.	O
To	O
explain	O
the	O
end-organ	O
resistance	O
to	O
cortisol	O
,	O
the	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
a	O
forearm	O
skin	O
biopsy	O
were	O
characterized	O
and	O
compared	O
with	O
the	O
results	O
of	O
similar	O
studies	O
in	O
normal	O
subjects	O
.	O
The	O
patient	O
's	O
GR	B-protein
in	O
whole	O
cell	O
assays	O
had	O
an	O
increased	O
dissociation	O
constant	O
(	O
Kd	O
)	O
.	O
In	O
the	O
cytosol	O
of	O
cultured	O
skin	O
fibroblasts	O
from	O
the	O
patient	O
,	O
there	O
was	O
also	O
decreased	O
binding	O
capacity	O
.	O
The	O
thermal	O
stability	O
and	O
the	O
sedimentation	O
coefficient	O
in	O
a	O
sucrose	O
density	O
gradient	O
of	O
the	O
receptors	O
in	O
the	O
cytosol	O
of	O
cultured	O
skin	O
fibroblasts	O
from	O
the	O
patient	O
and	O
normal	O
subjects	O
were	O
similar	O
.	O
GR	B-protein
complex	I-protein
activation	O
,	O
analyzed	O
by	O
DEAE-cellulose	O
chromatography	O
,	O
was	O
decreased	O
in	O
the	O
patient	O
.	O
DNA	O
binding	O
of	O
the	O
GR	B-protein
complex	I-protein
after	O
temperature-induced	O
activation	O
was	O
lower	O
in	O
the	O
patient	O
than	O
in	O
normal	O
subjects	O
.	O
Nuclear	O
translocation	O
of	O
GR	B-protein
complexes	I-protein
from	O
the	O
patient	O
was	O
also	O
slightly	O
decreased	O
.	O
These	O
results	O
suggest	O
that	O
the	O
patient	O
's	O
glucocorticoid	O
resistance	O
was	O
due	O
to	O
a	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
glucocorticoids	O
and	O
a	O
decrease	O
in	O
the	O
binding	O
of	O
the	O
GR	B-protein
complex	I-protein
to	O
DNA	O
.	O
Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O
Sensitive	O
and	O
receptor-mediated	O
regulation	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
.	O
We	O
show	O
that	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
[	O
OH	O
]	O
2D3	O
)	O
,	O
the	O
most	O
hormonally	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
modulates	O
sensitively	O
and	O
specifically	O
both	O
the	O
protein	O
and	O
messenger	O
RNA	O
accumulation	O
of	O
the	O
multilineage	B-protein
growth	I-protein
factor	I-protein
granulocyte-macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
.	O
The	O
regulation	O
of	O
GM-CSF	B-protein
expression	O
is	O
seen	O
in	O
both	O
normal	O
human	O
mitogen-activated	O
T	O
lymphocytes	O
and	O
T	O
lymphocytes	O
from	O
a	O
line	O
(	O
S-LB1	O
)	O
transformed	O
with	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
1	O
(	O
HTLV-1	O
)	O
.	O
In	O
contrast	O
,	O
cells	O
from	O
a	O
HTLV-1	O
transformed	O
T	O
lymphocyte	O
line	O
(	O
Ab-VDR	O
)	O
established	O
from	O
a	O
patient	O
with	O
vitamin	O
D-resistant	O
rickets	O
type	O
II	O
with	O
undetectable	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
cellular	O
receptors	O
are	O
resistant	O
to	O
the	O
action	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
Inhibition	O
of	O
GM-CSF	B-protein
expression	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
occur	O
independently	O
of	O
interleukin	B-protein
2	I-protein
regulation	I-protein
and	O
is	O
probably	O
mediated	O
through	O
cellular	B-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
.	O
We	O
conclude	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
may	O
be	O
important	O
in	O
the	O
physiology	O
of	O
hematopoiesis	O
.	O
Altered	O
interaction	O
between	O
triiodothyronine	O
and	O
its	O
nuclear	B-protein
receptors	I-protein
in	O
absence	O
of	O
cortisol	O
:	O
a	O
proposed	O
mechanism	O
for	O
increased	O
thyrotropin	O
secretion	O
in	O
corticosteroid	O
deficiency	O
states	O
.	O
Thyroid	O
hormones	O
occasionally	O
appear	O
less	O
effective	O
when	O
administered	O
alone	O
to	O
patients	O
with	O
panhypopituitarism	O
,	O
and	O
manifestations	O
suggestive	O
of	O
hypothyroidism	O
have	O
been	O
reported	O
in	O
patients	O
suffering	O
from	O
untreated	O
Addison	O
's	O
disease	O
.	O
In	O
the	O
latter	O
condition	O
,	O
thyrotropin	O
secretion	O
is	O
increased	O
:	O
this	O
occurs	O
already	O
after	O
as	O
little	O
as	O
2	O
days	O
of	O
temporary	O
withdrawal	O
of	O
therapy	O
with	O
substitution	O
doses	O
of	O
corticosteroids	O
while	O
circulating	O
levels	O
of	O
thyroid	O
hormones	O
remain	O
within	O
normal	O
limits	O
.	O
Therefore	O
,	O
a	O
possible	O
role	O
of	O
cortisol	O
in	O
interaction	O
between	O
triiodothyronine	O
and	O
its	O
nuclear	B-protein
receptors	I-protein
was	O
examined	O
at	O
the	O
level	O
of	O
circulating	O
lymphocytes	O
obtained	O
from	O
patients	O
with	O
primary	O
or	O
secondary	O
adrenocortical	O
failure	O
.	O
The	O
affinity	O
of	O
these	O
receptors	O
was	O
found	O
to	O
be	O
decreased	O
,	O
by	O
more	O
than	O
50	O
%	O
on	O
average	O
,	O
in	O
the	O
absence	O
of	O
cortisol	O
treatments	O
.	O
This	O
change	O
was	O
promptly	O
corrected	O
upon	O
resumption	O
of	O
therapy	O
.	O
The	O
number	O
of	O
binding	O
sites	O
was	O
not	O
significantly	O
modified	O
.	O
The	O
influence	O
of	O
cortisol	O
on	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
discussed	O
here	O
might	O
account	O
for	O
the	O
clinical	O
observations	O
mentioned	O
above	O
.	O
Inhibition	O
by	O
cortisol	O
of	O
human	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
.	O
The	O
effects	O
of	O
cortisol	O
on	O
the	O
natural	O
killer	O
(	O
NK	O
)	O
activity	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
(	O
PBM	O
)	O
cells	O
were	O
studied	O
in	O
vitro	O
using	O
a	O
direct	O
4-h	O
51Cr-release	O
assay	O
and	O
K	O
562	O
cell	O
line	O
as	O
a	O
target	O
.	O
Preincubation	O
for	O
20	O
h	O
of	O
PBM	O
cells	O
drawn	O
from	O
healthy	O
donors	O
with	O
1	O
X	O
10	O
(	O
-8	O
)	O
to	O
1	O
X	O
10	O
(	O
-5	O
)	O
M	O
cortisol	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
NK	O
cell	O
activity	O
.	O
The	O
magnitude	O
of	O
the	O
suppression	O
was	O
directly	O
related	O
to	O
the	O
steroid	O
concentration	O
and	O
inversely	O
related	O
to	O
the	O
number	O
of	O
effector	O
cells	O
.	O
Cortisol	O
was	O
able	O
to	O
minimize	O
the	O
enhancement	O
of	O
NK	O
cytotoxicity	O
obtainable	O
in	O
the	O
presence	O
of	O
immune	B-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
.	O
A	O
significantly	O
higher	O
suppression	O
was	O
achieved	O
after	O
sequential	O
exposure	O
of	O
PBM	O
cells	O
to	O
cortisol	O
and	O
equimolar	O
levels	O
of	O
prostaglandin	B-protein
E2	I-protein
(	O
PgE2	O
)	O
.	O
The	O
concomitant	O
incubation	O
with	O
theophylline	O
and	O
isobutyl-methylxanthine	O
failed	O
to	O
enhance	O
the	O
cortisol-induced	O
suppression	O
,	O
whereas	O
PgE2-dependent	O
inhibition	O
significantly	O
increased	O
after	O
exposure	O
of	O
PBM	O
cells	O
to	O
methyl-xanthines	O
.	O
The	O
inhibitory	O
effect	O
of	O
cortisol	O
was	O
partially	O
or	O
totally	O
prevented	O
by	O
the	O
concomitant	O
incubation	O
with	O
equimolar	O
amounts	O
of	O
11-deoxycortisol	O
and	O
RU	O
486	O
but	O
not	O
of	O
progesterone	O
.	O
Treatment	O
of	O
NK	O
effectors	O
with	O
a	O
monoclonal	B-protein
anti-human	I-protein
corticosteroid-binding	I-protein
globulin	I-protein
(	I-protein
CBG	I-protein
)	I-protein
antibody	I-protein
produced	O
an	O
enhancement	O
of	O
the	O
spontaneous	O
NK	O
activity	O
and	O
a	O
partial	O
suppression	O
of	O
cortisol-mediated	O
effects	O
.	O
Our	O
results	O
suggest	O
that	O
endogenous	O
glucocorticoids	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
NK	O
cell-mediated	O
cytotoxicity	O
.	O
Since	O
the	O
effect	O
of	O
cortisol	O
was	O
additive	O
to	O
that	O
of	O
PgE2	O
and	O
was	O
not	O
changed	O
by	O
phosphodiesterase	O
inhibitors	O
,	O
it	O
is	O
conceivable	O
that	O
the	O
hormone	B-protein
acts	O
at	O
a	O
level	O
different	O
from	O
the	O
adenylate	O
cyclase	O
-	O
phosphodiesterase	O
system	O
.	O
Data	O
obtained	O
with	O
the	O
use	O
of	O
antiglucocorticoids	O
and	O
the	O
anti-CBG	B-protein
antibody	I-protein
are	O
compatible	O
with	O
a	O
role	O
both	O
of	O
high-affinity	B-protein
glucocorticoid	I-protein
receptors	I-protein
and	O
of	O
CBG	O
in	O
mediating	O
cortisol	O
action	O
on	O
the	O
human	O
NK	O
cell	O
activity	O
.	O
Interaction	O
of	O
cell-type-specific	B-protein
nuclear	I-protein
proteins	I-protein
with	O
immunoglobulin	O
VH	O
promoter	O
region	O
sequences	O
.	O
All	O
human	O
and	O
murine	B-protein
immunoglobulin	I-protein
heavy	I-protein
chain	I-protein
variable	I-protein
region	I-protein
(	O
VH	O
)	O
genes	O
contain	O
the	O
sequence	O
ATGCAAAT	O
approximately	O
70	O
nucleotides	O
5	O
'	O
from	O
the	O
site	O
of	O
transcription	O
initiation	O
.	O
This	O
octanucleotide	O
,	O
in	O
reverse	O
orientation	O
,	O
is	O
also	O
found	O
in	O
all	O
light	O
chain	O
variable	O
region	O
(	O
VL	O
)	O
genes	O
,	O
and	O
in	O
the	O
immunoglobulin	O
heavy	O
chain	O
transcriptional	O
enhancer	O
.	O
Transfection	O
studies	O
have	O
established	O
that	O
this	O
octamer	O
is	O
involved	O
in	O
the	O
lymphoid-specific	O
transcription	O
of	O
immunoglobulin	O
genes	O
.	O
Octamer-containing	O
fragments	O
have	O
been	O
reported	O
to	O
bind	O
a	O
factor	O
present	O
in	O
nuclear	O
extracts	O
of	O
human	O
cell	O
lines	O
;	O
however	O
,	O
identical	O
binding	O
activity	O
was	O
detected	O
in	O
both	O
B	O
lymphoid	O
and	O
non-lymphoid	O
cells	O
.	O
Here	O
we	O
establish	O
that	O
nuclear	O
extracts	O
from	O
distinct	O
cell	O
types	O
differ	O
in	O
their	O
ability	O
to	O
interact	O
with	O
octamer-containing	O
fragments	O
.	O
We	O
have	O
also	O
detected	O
a	O
DNA-protein	O
interaction	O
that	O
may	O
be	O
involved	O
in	O
the	O
cell-type	O
specificity	O
of	O
immunoglobulin	O
expression	O
,	O
and	O
we	O
have	O
determined	O
that	O
a	O
sequence	O
upstream	O
of	O
the	O
octamer	O
participates	O
in	O
an	O
interaction	O
with	O
a	O
nuclear	B-protein
protein	I-protein
(	O
s	O
)	O
.	O
Preferential	O
transcription	O
of	O
HTLV-I	O
LTR	O
in	O
cell-free	O
extracts	O
of	O
human	O
T	O
cells	O
producing	O
HTLV-I	B-protein
viral	I-protein
proteins	I-protein
.	O
The	O
promoters	O
of	O
the	O
adenovirus	O
2	O
major	O
late	O
gene	O
,	O
the	O
mouse	O
beta-globin	O
gene	O
,	O
the	O
mouse	O
immunoglobulin	O
VH	O
gene	O
and	O
the	O
LTR	O
of	O
the	O
human	O
T-lymphotropic	O
retrovirus	O
type	O
I	O
were	O
tested	O
for	O
their	O
transcription	O
activities	O
in	O
cell-free	O
extracts	O
of	O
four	O
cell	O
lines	O
;	O
HeLa	O
,	O
CESS	O
(	O
Epstein-Barr	O
virus-transformed	O
human	O
B	O
cell	O
line	O
)	O
,	O
MT-1	O
(	O
HTLV-I-infected	O
human	O
T	O
cell	O
line	O
without	O
viral	B-protein
protein	I-protein
synthesis	O
)	O
,	O
and	O
MT-2	O
(	O
HTLV-I-infected	O
human	O
T	O
cell	O
line	O
producing	O
viral	B-protein
proteins	I-protein
)	O
.	O
LTR	O
was	O
preferentially	O
transcribed	O
in	O
the	O
extracts	O
of	O
MT-2	O
although	O
the	O
other	O
three	O
genes	O
were	O
transcribed	O
with	O
relatively	O
constant	O
efficiencies	O
in	O
different	O
extracts	O
.	O
The	O
results	O
agree	O
well	O
with	O
the	O
previous	O
in	O
vivo	O
studies	O
on	O
the	O
promoter	O
activity	O
of	O
HTLV-I	O
LTR	O
.	O
Mixing	O
of	O
HeLa	O
and	O
MT-2	O
extracts	O
revealed	O
the	O
presence	O
of	O
a	O
LTR-specific	O
stimulating	O
activity	O
in	O
MT-2	O
extracts	O
.	O
A	O
nuclear	O
factor	O
that	O
binds	O
to	O
a	O
conserved	O
sequence	O
motif	O
in	O
transcriptional	O
control	O
elements	O
of	O
immunoglobulin	O
genes	O
.	O
Trans-acting	B-protein
factors	I-protein
that	O
mediate	O
B-cell	O
specific	O
transcription	O
of	O
immunoglobulin	O
genes	O
have	O
been	O
postulated	O
based	O
on	O
an	O
analysis	O
of	O
the	O
expression	O
of	O
exogenously	O
introduced	O
immunoglobulin	O
gene	O
recombinants	O
in	O
lymphoid	O
and	O
non-lymphoid	O
cells	O
.	O
Two	O
B-cell-specific	O
,	O
cis-acting	O
transcriptional	O
regulatory	O
elements	O
have	O
been	O
identified	O
.	O
One	O
element	O
is	O
located	O
in	O
the	O
intron	O
between	O
the	O
variable	O
(	O
V	O
)	O
and	O
constant	O
(	O
C	O
)	O
regions	O
of	O
both	O
heavy	O
and	O
kappa	O
light-chain	O
genes	O
and	O
acts	O
as	O
a	O
transcriptional	O
enhancer	O
.	O
The	O
second	O
element	O
is	O
found	O
upstream	O
of	O
both	O
heavy	O
and	O
kappa	O
light-chain	O
gene	O
promoters	O
.	O
This	O
element	O
directs	O
lymphoid-specific	O
transcription	O
even	O
in	O
the	O
presence	O
of	O
viral	O
enhancers	O
.	O
We	O
have	O
sought	O
nuclear	B-protein
factors	I-protein
that	O
might	O
bind	O
specifically	O
to	O
these	O
two	O
regulatory	O
elements	O
by	O
application	O
of	O
a	O
modified	O
gel	O
electrophoresis	O
DNA	O
binding	O
assay	O
.	O
We	O
report	O
here	O
the	O
identification	O
of	O
a	O
human	O
B-cell	O
nuclear	O
factor	O
(	O
IgNF-A	O
)	O
that	O
binds	O
to	O
DNA	O
sequences	O
in	O
the	O
upstream	O
regions	O
of	O
both	O
the	O
mouse	O
heavy	O
and	O
kappa	O
light-chain	O
gene	O
promoters	O
and	O
also	O
to	O
the	O
mouse	O
heavy-chain	O
gene	O
enhancer	O
.	O
This	O
sequence-specific	O
binding	O
is	O
probably	O
mediated	O
by	O
a	O
highly	O
conserved	O
sequence	O
motif	O
,	O
ATTTGCAT	O
,	O
present	O
in	O
all	O
three	O
transcriptional	O
elements	O
.	O
Interestingly	O
,	O
a	O
factor	O
showing	O
similar	O
binding	O
specificity	O
to	O
IgNF-A	O
is	O
also	O
present	O
in	O
human	O
HeLa	O
cells	O
.	O
The	O
new	O
world	O
primates	O
as	O
animal	O
models	O
of	O
glucocorticoid	O
resistance	O
.	O
Many	O
New	O
World	O
primate	O
species	O
have	O
greatly	O
increased	O
plasma	O
cortisol	O
concentrations	O
,	O
decreased	O
plasma	O
cortisol	O
binding	O
globulin	O
capacity	O
and	O
affinity	O
,	O
marked	O
resistance	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
to	O
suppression	O
by	O
dexamethasone	O
,	O
and	O
no	O
biological	O
evidence	O
of	O
glucocorticoid	O
excess	O
.	O
These	O
primates	O
also	O
have	O
high	O
levels	O
of	O
circulating	O
progesterone	O
,	O
estrogen	O
,	O
mineralocorticoid	O
,	O
androgen	O
and	O
vitamin	O
D	O
.	O
The	O
glucocorticoid	O
target	O
tissues	O
that	O
have	O
been	O
examined	O
(	O
circulating	O
mononuclear	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
)	O
have	O
normal	O
concentrations	O
of	O
glucocorticoid	B-protein
receptors	I-protein
with	O
decreased	O
affinity	O
for	O
dexamethasone	O
.	O
Transformation	O
of	O
B-lymphocytes	O
with	O
the	O
Epstein-Barr	O
virus	O
leads	O
to	O
glucocorticoid	B-protein
receptor	I-protein
induction	O
that	O
is	O
less	O
than	O
that	O
observed	O
with	O
cells	O
from	O
Old	O
World	O
primates	O
.	O
The	O
receptor	O
in	O
these	O
cells	O
has	O
a	O
low	O
affinity	O
for	O
dexamethasone	O
.	O
The	O
low	O
affinity	O
leads	O
to	O
an	O
increased	O
loss	O
of	O
specific	O
bound	O
ligand	O
during	O
thermal	O
activation	O
.	O
Meroreceptor	O
generation	O
is	O
normal	O
.	O
The	O
molecular	O
weight	O
of	O
the	O
receptor	O
,	O
determined	O
by	O
SDS-PAGE	O
,	O
is	O
similar	O
to	O
that	O
of	O
Old	O
World	O
primates	O
(	O
approximately	O
92	O
,	O
000	O
)	O
and	O
the	O
activation	O
pattern	O
per	O
se	O
,	O
examined	O
in	O
vitro	O
by	O
heating	O
cytosol	O
and	O
performing	O
phosphocellulose	O
chromatography	O
,	O
appears	O
similar	O
to	O
that	O
of	O
human	O
controls	O
.	O
The	O
ratios	O
of	O
nuclear	O
to	O
cytosolic	O
hormone-receptor-complexes	O
and	O
of	O
cytosolic	O
activated	O
to	O
unactivated	B-protein
receptor	I-protein
complexes	I-protein
in	O
intact	O
cells	O
are	O
similar	O
to	O
Old	O
World	O
primates	O
.	O
Results	O
from	O
mixing	O
studies	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
a	O
binding	O
inhibitor	O
(	O
s	O
)	O
or	O
a	O
deficient	O
cytosolic	O
positive	O
modifier	O
(	O
s	O
)	O
of	O
binding	O
underlies	O
the	O
findings	O
in	O
these	O
primates	O
.	O
The	O
New	O
World	O
primates	O
,	O
unlike	O
men	O
with	O
the	O
syndrome	O
of	O
primary	O
cortisol	O
resistance	O
,	O
have	O
compensated	O
for	O
their	O
condition	O
with	O
intra-adrenal	O
and	O
mineralocorticoid	B-protein
receptor	I-protein
adaptations	O
.	O
Thus	O
,	O
unlike	O
Old	O
World	O
primates	O
,	O
cortisol	O
in	O
New	O
World	O
primates	O
has	O
only	O
weak	O
sodium-retaining	O
potency	O
because	O
the	O
aldosterone	O
receptor	O
has	O
a	O
low	O
affinity	O
for	O
cortisol	O
.	O
The	O
common	O
element	O
that	O
would	O
explain	O
the	O
apparent	O
resistance	O
to	O
six	O
steroid	O
hormones	O
in	O
New	O
World	O
primates	O
Acetylation	O
and	O
modulation	O
of	O
erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	O
)	O
activity	O
by	O
interaction	O
with	O
histone	B-protein
acetyltransferases	I-protein
.	O
Erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	O
)	O
is	O
a	O
red	B-protein
cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
that	O
is	O
crucial	O
for	O
consolidating	O
the	O
switch	O
to	O
high	O
levels	O
of	O
adult	O
beta-globin	O
expression	O
during	O
erythroid	O
ontogeny	O
.	O
EKLF	B-protein
is	O
required	O
for	O
integrity	O
of	O
the	O
chromatin	O
structure	O
at	O
the	O
beta-like	O
globin	O
locus	O
,	O
and	O
it	O
interacts	O
with	O
a	O
positive-acting	O
factor	O
in	O
vivo	O
.	O
We	O
find	O
that	O
EKLF	B-protein
is	O
an	O
acetylated	B-protein
transcription	I-protein
factor	I-protein
,	O
and	O
that	O
it	O
interacts	O
in	O
vivo	O
with	O
CBP	B-protein
,	O
p300	B-protein
,	O
and	O
P/CAF	O
.	O
However	O
,	O
its	O
interactions	O
with	O
these	O
histone	B-protein
acetyltransferases	I-protein
are	O
not	O
equivalent	O
,	O
as	O
CBP	B-protein
and	O
p300	B-protein
,	O
but	O
not	O
P/CAF	O
,	O
utilize	O
EKLF	O
as	O
a	O
substrate	O
for	O
in	O
vitro	O
acetylation	O
within	O
its	O
trans-activation	O
region	O
.	O
The	O
functional	O
effects	O
of	O
these	O
interactions	O
are	O
that	O
CBP	B-protein
and	O
p300	B-protein
,	O
but	O
not	O
P/CAF	O
,	O
enhance	O
EKLF	O
's	O
transcriptional	O
activation	O
of	O
the	O
beta-globin	O
promoter	O
in	O
erythroid	O
cells	O
.	O
These	O
results	O
establish	O
EKLF	O
as	O
a	O
tissue-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
undergoes	O
post-translational	O
acetylation	O
and	O
suggest	O
a	O
mechanism	O
by	O
which	O
EKLF	B-protein
is	O
able	O
to	O
alter	O
chromatin	O
structure	O
and	O
induce	O
beta-globin	O
expression	O
within	O
the	O
beta-like	O
globin	O
cluster	O
.	O
Recognition	O
of	O
herpes	O
simplex	O
virus	O
type	O
2	O
tegument	O
proteins	O
by	O
CD4	O
T	O
cells	O
infiltrating	O
human	O
genital	O
herpes	O
lesions	O
.	O
The	O
local	O
cellular	O
immune	O
response	O
to	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
is	O
important	O
in	O
the	O
control	O
of	O
recurrent	O
HSV	O
infection	O
.	O
The	O
antiviral	O
functions	O
of	O
infiltrating	O
CD4-bearing	O
T	O
cells	O
may	O
include	O
cytotoxicity	O
,	O
inhibition	O
of	O
viral	O
growth	O
,	O
lymphokine	O
secretion	O
,	O
and	O
support	O
of	O
humoral	O
and	O
CD8	O
responses	O
.	O
The	O
antigens	O
recognized	O
by	O
many	O
HSV-specific	O
CD4	O
T	O
cells	O
localizing	O
to	O
genital	O
HSV-2	O
lesions	O
are	O
unknown	O
.	O
T	O
cells	O
recognizing	O
antigens	B-protein
encoded	O
within	O
map	O
units	O
0.67	O
to	O
0.73	O
of	O
HSV	O
DNA	O
are	O
frequently	O
recovered	O
from	O
herpetic	O
lesions	O
.	O
Expression	O
cloning	O
with	O
this	O
region	O
of	O
DNA	O
now	O
shows	O
that	O
tegument	O
protein	O
VP22	O
and	O
the	O
viral	O
dUTPase	O
,	O
encoded	O
by	O
genes	O
UL49	O
and	O
UL50	O
,	O
respectively	O
,	O
are	O
T-cell	B-protein
antigens	I-protein
.	O
Separate	O
epitopes	O
in	O
VP22	O
were	O
defined	O
for	O
T-cell	O
clones	O
from	O
each	O
of	O
three	O
patients	O
.	O
Reactivity	O
with	O
the	O
tegument	O
protein	O
encoded	O
by	O
UL21	O
was	O
identified	O
for	O
an	O
additional	O
patient	O
.	O
Three	O
new	O
epitopes	O
were	O
identified	O
in	O
VP16	O
,	O
a	O
tegument	B-protein
protein	I-protein
associated	O
with	O
VP22	O
.	O
Some	O
tegument-specific	O
CD4	O
T-cell	O
clones	O
exhibited	O
cytotoxic	O
activity	O
against	O
HSV-infected	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
herpes	O
simplex	O
tegument	O
proteins	O
are	O
processed	O
for	O
antigen	O
presentation	O
in	O
vivo	O
and	O
are	O
possible	O
candidate	O
compounds	O
for	O
herpes	O
simplex	O
vaccines	O
.	O
Fibrinogen	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factors	I-protein
in	O
mononuclear	O
phagocytes	O
.	O
Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O
Mononuclear	O
phagocytes	O
are	O
exposed	O
to	O
fibrinous	O
provisional	O
matrix	O
throughout	O
migration	O
into	O
inflammatory	O
foci	O
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
fibrinogen	O
triggers	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factors	I-protein
.	O
U937	O
cells	O
differentiated	O
with	O
PMA	O
in	O
nonadherent	O
culture	O
were	O
shown	O
to	O
express	O
two	O
fibrinogen-binding	O
integrins	O
,	O
predominately	O
CD11b/CD18	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
CD11c/CD18	O
.	O
Cells	O
stimulated	O
with	O
fibrinogen	O
(	O
10-100	O
microg/ml	O
)	O
/Mn2+	O
(	O
50	O
microM	O
)	O
for	O
2	O
h	O
were	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
minimal	O
in	O
unstimulated	O
cells	O
,	O
was	O
substantially	O
up-regulated	O
by	O
fibrinogen	B-protein
.	O
Fibrinogen	B-protein
also	O
caused	O
activation	O
of	O
AP-1	B-protein
,	O
but	O
not	O
SP1	B-protein
or	O
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	I-protein
factors	I-protein
.	O
Blocking	O
mAbs	O
against	O
CD18	B-protein
and	O
CD11b	B-protein
abrogated	O
fibrinogen	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
To	O
determine	O
the	O
effects	O
on	O
transcriptional	O
regulation	O
,	O
U937	O
cells	O
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
HIV-1	O
enhancer	O
(	O
bearing	O
two	O
NF-kappa	O
B	O
sites	O
)	O
coupled	O
to	O
a	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	O
)	O
reporter	O
.	O
Cells	O
were	O
subsequently	O
stimulated	O
with	O
1	O
)	O
PMA	O
for	O
24	O
h	O
,	O
inducing	O
CAT	O
activity	O
by	O
2.6-fold	O
,	O
2	O
)	O
fibrinogen	O
/Mn2+	O
for	O
2	O
h	O
,	O
inducing	O
CAT	O
activity	O
by	O
3.2-fold	O
,	O
or	O
3	O
)	O
costimulation	O
with	O
fibrinogen	B-protein
and	O
PMA	O
,	O
inducing	O
5.7-fold	O
the	O
CAT	O
activity	O
induced	O
by	O
PMA	O
alone	O
.	O
We	O
conclude	O
that	O
contact	O
with	O
fibrinogen-derived	B-protein
proteins	I-protein
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
CD11b/CD18	O
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	B-protein
regulatory	I-protein
factors	I-protein
,	O
including	O
NF-kappa	B-protein
B	I-protein
.	O
Peripheral	O
blood	O
T	O
cells	O
and	O
monocytes	O
and	O
B	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
lupus	O
express	O
estrogen	B-protein
receptor	I-protein
transcripts	O
similar	O
to	O
those	O
of	O
normal	O
cells	O
.	O
OBJECTIVE	O
:	O
To	O
identify	O
and	O
characterize	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
transcripts	O
expressed	O
in	O
immune	O
cells	O
of	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
healthy	O
donors	O
.	O
METHODS	O
:	O
Peripheral	O
blood	O
monocytes	O
and	O
T	O
cells	O
were	O
prepared	O
from	O
patients	O
with	O
SLE	O
(	O
n	O
=	O
6	O
)	O
and	O
healthy	O
donors	O
(	O
n	O
=	O
8	O
)	O
.	O
T	O
cells	O
were	O
separated	O
into	O
CD4	O
and	O
CD8	O
.	O
Some	O
monocytes	O
and	O
T	O
cells	O
were	O
stimulated	O
with	O
estradiol	O
,	O
PMA	O
,	O
and	O
ionomycin	O
.	O
Epstein-Barr	O
virus-transformed	O
B	O
cell	O
lines	O
(	O
n	O
=	O
7	O
)	O
and	O
B	O
cell	O
hybridomas	O
(	O
n	O
=	O
2	O
)	O
established	O
from	O
patients	O
with	O
SLE	O
and	O
a	O
healthy	O
individual	O
were	O
used	O
as	O
a	O
B	O
cell	O
source	O
.	O
These	O
cells	O
were	O
examined	O
for	O
ER	O
mRNA	O
by	O
reverse	O
transcription	O
nested	O
polymerase	O
chain	O
reaction	O
.	O
Amplified	O
cDNA	O
were	O
sequenced	O
by	O
standard	O
methods	O
.	O
RESULTS	O
:	O
In	O
all	O
cells	O
tested	O
,	O
ER	O
mRNA	O
was	O
expressed	O
without	O
prior	O
in	O
vitro	O
stimulation	O
.	O
Partial	O
sequences	O
from	O
exons	O
1-8	O
were	O
nearly	O
identical	O
to	O
the	O
published	O
sequence	O
of	O
the	O
human	O
ER	O
mRNA	O
.	O
There	O
were	O
no	O
notable	O
differences	O
in	O
the	O
ER	O
transcripts	O
between	O
patients	O
and	O
healthy	O
controls	O
.	O
Variant	O
receptor	O
transcripts	O
lacking	O
exon	O
5	O
or	O
exon	O
7	O
,	O
which	O
encodes	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
,	O
were	O
identified	O
in	O
the	O
majority	O
of	O
the	O
cells	O
.	O
Precise	O
deletion	O
of	O
the	O
exons	O
suggests	O
that	O
they	O
are	O
alternatively	O
spliced	O
transcripts	O
.	O
Whether	O
the	O
detected	O
transcripts	O
are	O
translated	O
into	O
functional	B-protein
receptor	I-protein
proteins	I-protein
remains	O
to	O
be	O
determined	O
.	O
In	O
vitro	O
stimulation	O
did	O
not	O
affect	O
ER	O
mRNA	O
expression	O
.	O
The	O
presence	O
of	O
variants	O
did	O
not	O
correlate	O
with	O
disease	O
activity	O
or	O
medication	O
.	O
CONCLUSION	O
:	O
Monocytes	O
,	O
T	O
cells	O
,	O
and	O
B	O
cells	O
in	O
patients	O
express	O
transcripts	O
of	O
the	O
normal	O
wild	O
type	O
ER	B-protein
and	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
variants	O
in	O
vivo	O
.	O
DNA	O
damaging	O
agents	O
induce	O
expression	O
of	O
Fas	B-protein
ligand	O
and	O
subsequent	O
apoptosis	O
in	O
T	O
lymphocytes	O
via	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
.	O
Apoptosis	O
induced	O
by	O
DNA	O
damage	O
and	O
other	O
stresses	O
can	O
proceed	O
via	O
expression	O
of	O
Fas	B-protein
ligand	O
(	O
FasL	O
)	O
and	O
ligation	O
of	O
its	O
receptor	O
,	O
Fas	B-protein
(	O
CD95	B-protein
)	O
.	O
We	O
report	O
that	O
activation	O
of	O
the	O
two	O
transcription	O
factors	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
is	O
crucially	O
involved	O
in	O
FasL	O
expression	O
induced	O
by	O
etoposide	O
,	O
teniposide	O
,	O
and	O
UV	O
irradiation	O
.	O
A	O
nondegradable	O
mutant	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
blocked	O
both	O
FasL	O
expression	O
and	O
apoptosis	O
induced	O
by	O
DNA	O
damage	O
but	O
not	O
Fas	O
ligation	O
.	O
These	O
stimuli	O
also	O
induced	O
the	O
stress-activated	O
kinase	O
pathway	O
(	O
SAPK/JNK	O
)	O
,	O
which	O
was	O
required	O
for	O
the	O
maximal	O
induction	O
of	O
apoptosis	O
.	O
A	O
1.2	O
kb	O
FasL	O
promoter	O
responded	O
to	O
DNA	O
damage	O
,	O
as	O
well	O
as	O
coexpression	O
with	O
p65	B-protein
Rel	I-protein
or	O
Fos/Jun	O
.	O
Mutations	O
in	O
the	O
relevant	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
binding	O
sites	O
eliminated	O
these	O
responses	O
.	O
Thus	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
contributes	O
to	O
stress-induced	O
apoptosis	O
via	O
the	O
expression	O
of	O
FasL	B-protein
.	O
A	O
small	O
,	O
nonpeptidyl	O
mimic	O
of	O
granulocyte-colony-stimulating	O
factor	O
[	O
see	O
commetns	O
]	O
A	O
nonpeptidyl	O
small	O
molecule	O
SB	O
247464	O
,	O
capable	O
of	O
activating	B-protein
granulocyte-colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
signal	O
transduction	O
pathways	O
,	O
was	O
identified	O
in	O
a	O
high-throughput	O
assay	O
in	O
cultured	O
cells	O
.	O
Like	O
G-CSF	B-protein
,	O
SB	O
247464	O
induced	O
tyrosine	O
phosphorylation	O
of	O
multiple	O
signaling	B-protein
proteins	I-protein
and	O
stimulated	O
primary	O
murine	O
bone	O
marrow	O
cells	O
to	O
form	O
granulocytic	O
colonies	O
in	O
vitro	O
.	O
It	O
also	O
elevated	O
peripheral	O
blood	O
neutrophil	O
counts	O
in	O
mice	O
.	O
The	O
extracellular	B-protein
domain	I-protein
of	O
the	O
murine	O
G-CSF	B-protein
receptor	I-protein
was	O
required	O
for	O
the	O
activity	O
of	O
SB	O
247464	O
,	O
suggesting	O
that	O
the	O
compound	O
acts	O
by	O
oligomerizing	B-protein
receptor	I-protein
chains	I-protein
.	O
The	O
results	O
indicate	O
that	O
a	O
small	O
molecule	O
can	O
activate	O
a	O
receptor	O
that	O
normally	O
binds	O
a	O
relatively	O
large	O
protein	O
ligand	O
.	O
Minimal	O
residual	O
disease	O
in	O
acute	O
myelogenous	O
leukemia	O
with	O
PML/RAR	B-protein
alpha	I-protein
or	O
AML1/ETO	O
mRNA	O
and	O
phenotypic	O
analysis	O
of	O
possible	O
T	O
and	O
natural	O
killer	O
cells	O
in	O
bone	O
marrow	O
.	O
Here	O
we	O
studied	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
who	O
have	O
PML/RAR	O
alpha	O
or	O
AML1/ETO	B-protein
as	O
well	O
as	O
the	O
phenotypic	O
analysis	O
of	O
lymphocyte	O
subsets	O
involved	O
in	O
antitumor	O
immunity	O
.	O
Eight	O
patients	O
in	O
long-term	O
(	O
LT	O
;	O
3	O
to	O
15	O
years	O
)	O
and	O
15	O
patients	O
in	O
short-term	O
(	O
ST	O
;	O
up	O
to	O
3	O
years	O
)	O
remission	O
were	O
studied	O
.	O
Using	O
the	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
RT	O
)	O
assay	O
,	O
the	O
limit	O
of	O
detection	O
was	O
10	O
(	O
-5	O
)	O
to	O
10	O
(	O
-6	O
)	O
for	O
PML/RAR	O
alpha	O
transcript	O
and	O
10	O
(	O
-4	O
)	O
to	O
10	O
(	O
-5	O
)	O
for	O
the	O
AML1/ETO	O
transcript	O
.	O
Simultaneously	O
,	O
T	O
lymphocyte	O
subsets	O
and	O
NK	O
cells	O
from	O
the	O
peripheral	O
blood	O
(	O
PB	O
)	O
and	O
bone	O
marrow	O
(	O
BM	O
)	O
were	O
investigated	O
by	O
flow	O
cytometric	O
analysis	O
.	O
Four	O
of	O
the	O
eight	O
patients	O
in	O
LT	O
and	O
7	O
of	O
the	O
15	O
patients	O
in	O
ST	O
remission	O
were	O
MRD-positive	O
.	O
Although	O
all	O
MRD-positive	O
patients	O
in	O
LT	O
remission	O
are	O
still	O
until	O
now	O
event-free	O
,	O
3	O
of	O
the	O
7	O
MRD-positive	O
(	O
MRD+	O
)	O
patients	O
in	O
ST	O
remission	O
soon	O
relapsed	O
.	O
The	O
total	O
populations	O
of	O
CD4	B-protein
+	O
,	O
CD8	O
+	O
and	O
CD56	O
+	O
[	O
possible	O
T-cell	O
and	O
natural	O
killer	O
(	O
T/NK	O
)	O
populations	O
]	O
in	O
the	O
BM	O
of	O
ST	O
patients	O
and	O
MRD+/LT	O
patients	O
were	O
significantly	O
(	O
p	O
<	O
.01	O
)	O
low	O
.	O
The	O
CD8+	O
CD28+	O
population	O
showed	O
the	O
same	O
tendency	O
(	O
p	O
<	O
.01-.02	O
)	O
.	O
The	O
T/NK	O
subsets	O
in	O
the	O
BM	O
of	O
MRD-negative	O
(	O
MRD-	O
)	O
LT	O
(	O
MRD-/LT	O
)	O
patients	O
showed	O
similar	O
numbers	O
of	O
cells	O
as	O
normal	O
volunteers	O
.	O
Basically	O
,	O
the	O
total	O
percentage	O
of	O
the	O
CD4+	O
,	O
CD8+	O
and	O
CD56+	O
cell	O
populations	O
in	O
the	O
BM	O
was	O
increased	O
and	O
in	O
the	O
following	O
order	O
:	O
MRD-/LT	O
patients	O
,	O
normal	O
volunteers	O
,	O
MRD+/LT	O
patients	O
and	O
MRD+	B-protein
or	O
-/ST	O
patients	O
.	O
The	O
percentages	O
of	O
the	O
T/NK-cell	O
subsets	O
in	O
the	O
PB	O
were	O
not	O
significantly	O
different	O
among	O
these	O
groups	O
.	O
Thus	O
,	O
the	O
difference	O
of	O
the	O
possible	O
T/NK-cell	O
phenotype	O
in	O
the	O
BM	O
may	O
strongly	O
influence	O
clinical	O
and	O
molecular	O
remission	O
.	O
These	O
results	O
still	O
remain	O
to	O
be	O
confirmed	O
by	O
further	O
studies	O
of	O
the	O
functional	O
anti-tumor	O
immunity	O
of	O
T/NK	O
cells	O
of	O
AML	O
in	O
remission	O
.	O
Mycobacterium	O
tuberculosis	O
mannose-capped	O
lipoarabinomannan	O
can	O
induce	O
NF-kappaB	B-protein
-dependent	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
T	O
cells	O
.	O
Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O
The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	O
cell	O
wall	O
component	O
mannose-capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV-1	O
in	O
T	O
cells	O
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O
These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4	O
-expressing	O
T	O
lymphocytes	O
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O
Using	O
the	O
1G5	O
cell	O
line	O
harbouring	O
the	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV-1	O
LTR	O
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
CFP	O
)	O
from	O
M.	O
tuberculosis	O
or	O
purified	O
ManLAM	O
could	O
activate	O
HIV-1	O
LTR-dependent	O
gene	O
expression	O
unlike	O
similarly	O
prepared	O
CFP	O
extracts	O
devoid	O
of	O
ManLAM	O
.	O
The	O
implication	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
s	O
)	O
,	O
protein	B-protein
kinase	I-protein
A	I-protein
and/or	I-protein
protein	I-protein
kinase	I-protein
C	I-protein
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM-mediated	O
activation	O
of	O
HIV-1	O
LTR-driven	O
gene	O
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O
It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
M.	O
tuberculosis	O
ManLAM	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O
M.	O
tuberculosis	O
ManLAM	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	O
gene	O
placed	O
under	O
the	O
control	O
of	O
the	O
wild-type	O
,	O
but	O
not	O
the	O
kappaB-mutated	O
,	O
HIV-1	O
LTR	O
region	O
.	O
Finally	O
,	O
the	O
ManLAM-mediated	O
activation	O
of	O
HIV-1	O
LTR	O
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	O
TNF-alpha	B-protein
.	O
The	O
results	O
suggest	O
that	O
M.	O
tuberculosis	O
can	O
upregulate	O
HIV-1	O
expression	O
in	O
T	O
cells	O
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
.	O
Human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
quasispecies	O
differ	O
in	O
basal	O
transcription	O
and	O
nuclear	B-protein
factor	I-protein
recruitment	O
in	O
human	O
glial	O
cells	O
and	O
lymphocytes	O
.	O
The	O
generation	O
of	O
genomic	O
diversity	O
during	O
the	O
course	O
of	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
all	O
aspects	O
of	O
HIV-1	O
replication	O
,	O
including	O
expression	O
of	O
the	O
proviral	O
genome	O
.	O
To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
impact	O
of	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
sequence	O
diversity	O
on	O
LTR-directed	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
immune	O
system	O
,	O
we	O
amplified	O
and	O
cloned	O
LTRs	O
from	O
proviral	O
DNA	O
in	O
HIV-1-infected	O
peripheral	O
blood	O
.	O
Sequence	O
analysis	O
of	O
nineteen	O
LTRs	O
cloned	O
from	O
2	O
adult	O
and	O
3	O
pediatric	O
patients	O
revealed	O
an	O
average	O
of	O
33	O
nucleotide	O
changes	O
(	O
with	O
respect	O
to	O
the	O
sequence	O
of	O
the	O
LAI	O
LTR	O
)	O
within	O
the	O
455-bp	O
U3	O
region	O
.	O
Transient	O
expression	O
analyses	O
in	O
cells	O
of	O
neuroglial	O
and	O
lymphocytic	O
origin	O
demonstrated	O
that	O
some	O
of	O
these	O
LTRs	O
had	O
activities	O
which	O
varied	O
significantly	O
from	O
the	O
LAI	O
LTR	O
in	O
U-373	O
MG	O
cells	O
(	O
an	O
astrocytoma	O
cell	O
line	O
)	O
as	O
well	O
as	O
in	O
Jurkat	O
cells	O
(	O
a	O
CD4-positive	O
lymphocyte	O
cell	O
line	O
)	O
.	O
While	O
LTRs	O
which	O
demonstrated	O
the	O
highest	O
activities	O
in	O
U-373	O
MG	O
cells	O
also	O
yielded	O
high	O
activities	O
in	O
Jurkat	O
cells	O
,	O
the	O
LTRs	O
were	O
generally	O
more	O
active	O
in	O
Jurkat	O
cells	O
when	O
compared	O
to	O
the	O
LAI	O
LTR	O
.	O
Differences	O
in	O
LTR	O
sequence	O
also	O
resulted	O
in	O
differences	O
in	O
transcription	B-protein
factor	I-protein
recruitment	O
to	O
cis-acting	O
sites	O
within	O
the	O
U3	O
region	O
of	O
the	O
LTR	O
,	O
as	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
In	O
particular	O
,	O
naturally	O
occurring	O
sequence	O
variation	O
impacted	O
transcription	O
factor	O
binding	O
to	O
an	O
activating	B-protein
transcription	I-protein
factor	I-protein
/	O
cAMP	O
response	O
element	O
binding	O
(	O
ATF	B-protein
/	O
CREB	B-protein
)	O
binding	O
site	O
(	O
located	O
between	O
the	O
LEF-1	B-protein
and	O
distal	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
binding	I-protein
sites	I-protein
)	O
that	O
we	O
identified	O
in	O
previous	O
studies	O
of	O
the	O
HIV-1	O
LTR	O
.	O
These	O
findings	O
suggest	O
that	O
LTR	O
sequence	O
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	O
function	O
and	O
transcription	B-protein
factor	I-protein
recruitment	I-protein
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O
HMG	O
box	O
containing	O
transcription	B-protein
factors	I-protein
in	O
lymphocyte	O
differentiation	O
.	O
The	O
identification	O
of	O
the	O
mammalian	O
sex-determining	O
gene	O
Sry	O
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
large	O
family	O
of	O
related	O
(	O
'	O
HMG	O
box	O
'	O
)	O
transcription	B-protein
factors	I-protein
that	O
control	O
developmental	O
events	O
in	O
yeast	O
,	O
C.	O
elegans	O
,	O
Drosophila	O
and	O
vertebrates	O
.	O
In	O
lymphocyte	O
differentiation	O
,	O
several	O
HMG	O
box	O
proteins	O
play	O
a	O
decisive	O
role	O
.	O
Sox-4	O
is	O
important	O
for	O
very	O
early	O
B-cell	O
differentiation	O
,	O
while	O
TCF-1	B-protein
/	O
LEF-1	B-protein
play	O
a	O
crucial	O
role	O
in	O
early	O
thymocyte	O
development	O
.	O
TCF/LEF	B-protein
proteins	I-protein
have	O
recently	O
been	O
found	O
to	O
constitute	O
a	O
downstream	O
component	O
of	O
the	O
Wingless/Wnt	O
signal	O
transduction	O
pathway	O
.	O
In	O
flies	O
,	O
this	O
pathway	O
controls	O
segment	O
polarity	O
;	O
in	O
Xenopus	O
it	O
controls	O
the	O
definition	O
of	O
the	O
body	O
axis	O
.	O
Deregulation	O
of	O
the	O
pathway	O
occurs	O
in	O
several	O
human	O
tumors	O
.	O
These	O
insights	O
in	O
the	O
molecular	O
events	O
that	O
are	O
involved	O
in	O
TCF/LEF	O
function	O
in	O
these	O
organisms	O
may	O
eventually	O
lead	O
to	O
the	O
understanding	O
of	O
the	O
function	O
of	O
these	O
HMG	O
box	O
proteins	O
in	O
lymphoid	O
development	O
Transcriptional	O
regulation	O
by	O
C/EBP	B-protein
alpha	I-protein
and	O
-beta	O
in	O
the	O
expression	O
of	O
the	O
gene	O
for	O
the	O
MRP14	O
myeloid	O
calcium	O
binding	O
protein	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
gene	O
for	O
the	O
myeloid	O
calcium	O
binding	O
protein	O
,	O
MRP14	O
,	O
was	O
investigated	O
in	O
human	O
monocytic	O
leukemia	O
cell	O
lines	O
.	O
The	O
MRP14	O
gene	O
was	O
not	O
expressed	O
in	O
monoblastic	O
ML-1	O
cells	O
,	O
promonocytic	O
U-937	O
cells	O
,	O
or	O
promyelocytic	O
HL-60	O
cells	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
gene	O
was	O
expressed	O
in	O
monocytic	O
THP-1	O
cells	O
and	O
in	O
the	O
HL-60	O
cells	O
treated	O
with	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
.	O
The	O
level	O
of	O
MRP14	O
in	O
VD3-treated	O
HL-60	O
cells	O
was	O
two-fold	O
higher	O
than	O
that	O
in	O
THP-1	O
cells	O
.	O
Among	O
several	O
known	O
transcription	B-protein
factor	I-protein
binding	I-protein
motifs	I-protein
,	O
nuclear	B-protein
protein	I-protein
(	O
s	O
)	O
of	O
VD3-treated	O
HL-60	O
cells	O
and	O
THP-1	O
cells	O
bound	O
to	O
the	O
CCAAT/enhancer	B-protein
binding	I-protein
protein	I-protein
(	O
C/EBP	O
)	O
-binding	O
motif	O
that	O
was	O
located	O
in	O
the	O
upstream	O
region	O
of	O
the	O
MRP14	O
gene	O
(	O
-81	O
)	O
,	O
as	O
evidenced	O
by	O
the	O
competitive	O
gel	O
mobility-shift	O
assay	O
.	O
An	O
antibody	O
for	O
C/EBP	O
alpha	O
super-shifted	O
the	O
nucleoprotein	O
complex	O
in	O
THP-1	O
cells	O
but	O
not	O
in	O
the	O
VD3-treated	O
HL-60	O
cells	O
,	O
whereas	O
an	O
antibody	O
for	O
C/EBP	B-protein
beta	I-protein
blocked	O
the	O
formation	O
of	O
the	O
complex	O
with	O
the	O
nuclear	B-protein
factor	I-protein
of	O
the	O
HL-60	O
cells	O
but	O
not	O
with	O
that	O
of	O
THP-1	O
cells	O
.	O
An	O
anti-C/EBP	B-protein
delta	I-protein
antibody	I-protein
had	O
no	O
effect	O
on	O
the	O
complex	O
in	O
either	O
cell	O
.	O
Thus	O
,	O
it	O
was	O
concluded	O
that	O
C/EBP	B-protein
alpha	I-protein
and	O
-beta	O
were	O
able	O
to	O
bind	O
to	O
the	O
C/EBP	O
motif	O
,	O
and	O
that	O
C/EBP	B-protein
alpha	I-protein
bound	O
to	O
the	O
motif	O
in	O
THP-1	O
cells	O
and	O
C/EBP	B-protein
beta	I-protein
bound	I-protein
to	O
that	O
in	O
the	O
VD3-treated	O
HL-60	O
cells	O
.	O
Furthermore	O
,	O
to	O
examine	O
the	O
transcriptional	O
activity	O
of	O
the	O
C/EBP	O
motif	O
,	O
we	O
transfected	O
several	O
constructed	O
luciferase	O
reporter	O
DNAs	O
into	O
HL-60	O
cells	O
and	O
THP-1	O
cells	O
.	O
The	O
luciferase	O
activity	O
of	O
the	O
C/EBP	O
motif	O
in	O
HL-60	O
cells	O
was	O
increased	O
by	O
VD3	O
treatment	O
.	O
The	O
C/EBP	O
motif	O
in	O
the	O
MRP14	O
gene	O
was	O
confirmed	O
to	O
function	O
as	O
a	O
regulatory	O
region	O
in	O
VD3-treated	O
HL-60	O
cells	O
and	O
THP-1	O
cells	O
by	O
the	O
assay	O
.	O
Since	O
C/EBP	B-protein
beta	I-protein
was	O
also	O
detected	O
in	O
VD3-untreated	O
HL-60	O
cells	O
by	O
immunoblotting	O
,	O
VD3	O
activated	O
C/EBP	B-protein
beta	I-protein
to	O
bind	O
to	O
the	O
motif	O
,	O
probably	O
through	O
post-translational	O
modification	O
.	O
Patients	O
with	O
high-risk	O
myelodysplastic	O
syndrome	O
can	O
have	O
polyclonal	O
or	O
clonal	O
haemopoiesis	O
in	O
complete	O
haematological	O
remission	O
.	O
The	O
clonality	O
of	O
mature	O
peripheral	O
blood-derived	O
myeloid	O
and	O
lymphoid	O
cells	O
and	O
bone	O
marrow	O
haemopoietic	O
progenitors	O
from	O
18	O
females	O
with	O
myelodysplasia	O
(	O
MDS	O
)	O
(	O
five	O
refractory	O
anaemia	O
,	O
RA	O
;	O
one	O
RA	O
with	O
ringed	O
sideroblasts	O
,	O
RARS	B-protein
;	O
three	O
chronic	O
myelomonocytic	O
leukaemia	O
,	O
CMML	O
;	O
four	O
RA	O
with	O
excess	O
of	O
blasts	O
,	O
RAEB	O
;	O
five	O
RAEB	O
in	O
transformation	O
,	O
RAEB-t	O
)	O
was	O
studied	O
by	O
X-chromosome	O
inactivation	O
analysis	O
.	O
Using	O
the	O
human	O
androgen-receptor	O
(	O
HUMARA	O
)	O
assay	O
,	O
we	O
analysed	O
the	O
clonal	O
patterns	O
of	O
highly	O
purified	O
immature	O
CD34+	O
38-	O
and	O
committed	O
CD34+	O
38+	O
marrow-derived	O
progenitors	O
,	O
and	O
CD16+	O
14-	O
granulocytes	O
,	O
CD14+	O
monocytes	O
,	O
CD3+	O
T	O
and	O
CD19+	O
B	O
lymphocytes	O
from	O
peripheral	O
blood	O
.	O
In	O
high-risk	O
patients	O
(	O
RAEB	O
,	O
RAEB-t	O
)	O
,	O
clonality	O
analysis	O
was	O
performed	O
before	O
and	O
after	O
intensive	O
remission-induction	O
treatment	O
.	O
All	O
patients	O
,	O
except	O
one	O
with	O
RA	O
,	O
had	O
predominance	O
of	O
a	O
single	O
clone	O
in	O
their	O
granulocytes	O
and	O
monocytes	O
.	O
The	O
same	O
clonal	O
pattern	O
was	O
found	O
in	O
CD34+	O
progenitor	O
cells	O
.	O
In	O
contrast	O
,	O
CD3+	O
T	O
lymphocytes	O
were	O
polyclonal	O
or	O
oligoclonal	O
in	O
14/18	O
patients	O
.	O
X-chromosome	O
inactivation	O
patterns	O
of	O
CD19+	O
B	O
cells	O
were	O
highly	O
concordant	O
with	O
CD3+	O
T	O
cells	O
except	O
for	O
two	O
patients	O
(	O
one	O
RA	O
,	O
one	O
CMML	O
)	O
with	O
monoclonal	B-protein
B	I-protein
and	O
polyclonal	O
T	O
lymphocytes	O
,	O
therefore	O
suggesting	O
a	O
clonal	O
mutation	O
in	O
a	O
progenitor	O
common	O
to	O
the	O
myeloid	O
and	O
B-lymphoid	O
lineages	O
or	O
the	O
coexistence	O
of	O
MDS	B-protein
and	O
a	O
B-cell	O
disorder	O
in	O
these	O
particular	O
patients	O
.	O
After	O
high-dose	O
non-myeloablative	O
chemotherapy	O
,	O
polyclonal	O
haemopoiesis	O
was	O
reinstalled	O
in	O
the	O
mature	O
myeloid	O
cells	O
and	O
immature	O
and	O
committed	O
marrow	O
progenitors	O
in	O
three	O
of	O
four	O
patients	O
achieving	O
complete	O
haematological	O
remission	O
.	O
Therefore	O
we	O
conclude	O
that	O
most	O
haematological	O
remissions	O
in	O
MDS	O
are	O
associated	O
with	O
restoration	O
of	O
polyclonal	O
haemopoiesis	O
.	O
Prominent	O
sex	O
steroid	O
metabolism	O
in	O
human	O
lymphocytes	O
.	O
Steroid	O
metabolism	O
was	O
investigated	O
in	O
cultured	O
human	O
B-lymphoblastoid	O
cells	O
(	O
B-LCL	O
)	O
,	O
and	O
peripheral	O
blood	O
T	O
and	O
B	O
cells	O
.	O
Gene	O
expression	O
was	O
examined	O
by	O
reverse-transcription	O
polymerase	O
chain	O
reaction	O
amplification	O
(	O
RT-PCR	O
)	O
.	O
Appropriate	O
sized	O
transcripts	O
were	O
detected	O
in	O
both	O
cultured	O
and	O
fresh	O
peripheral	O
lymphocytes	O
for	O
CYP11A	O
,	O
CYP17	O
,	O
HSD11L	O
(	O
11beta-hydroxysteroid	O
dehydrogenase	O
I	O
)	O
,	O
HSD17B1	O
(	O
17beta-hydroxysteroid	O
dehydrogenase	O
type	O
I	O
)	O
and	O
SRD5A1	O
(	O
5alpha-reductase	B-protein
I	I-protein
)	I-protein
.	O
B-LCL	O
,	O
but	O
not	O
T	O
and	O
B	O
cells	O
,	O
expressed	O
CYP11B	O
.	O
There	O
was	O
minimal	O
expression	O
of	O
HSD3B1	B-protein
and	O
HSD3B2	O
(	O
3beta-hydroxysteroid	B-protein
dehydrogenase	I-protein
I	I-protein
and	I-protein
II	I-protein
)	O
in	O
B-LCL	O
and	O
T	O
cells	O
.	O
Transcripts	O
for	O
CYP19	O
and	O
HSD11K	O
were	O
not	O
detected	O
.	O
Corresponding	O
enzymatic	O
activity	O
was	O
detectable	O
only	O
for	O
17-hydroxysteroid	O
dehydrogenase	O
and	O
5alpha-reductase	O
,	O
respectively	O
producing	O
testosterone	O
and	O
5alpha-dihydrotestosterone	O
.	O
Steroid	O
identities	O
were	O
confirmed	O
by	O
gas	O
chromatography/mass	O
spectrometry	O
(	O
GC/MS	O
)	O
.	O
One	O
metabolite	O
thought	O
to	O
be	O
deoxycorticosterone	O
was	O
identified	O
by	O
GC/MS	B-protein
as	O
6alpha-hydroxypregnanolone	O
.	O
It	O
was	O
concluded	O
that	O
sex	O
hormone	O
metabolism	O
,	O
including	O
androgen	O
synthesis	O
,	O
occurs	O
in	O
lymphocytes	O
,	O
and	O
may	O
modulate	O
immune	O
response	O
.	O
Human	O
white	O
blood	O
cells	O
and	O
hair	O
follicles	O
are	O
good	O
sources	O
of	O
mRNA	O
for	O
the	O
pterin	O
carbinolamine	O
dehydratase/dimerization	O
cofactor	O
of	O
HNF1	O
for	O
mutation	O
detection	O
.	O
Pterin	O
carbinolamine	O
dehydratase/dimerization	O
cofactor	O
of	O
HNF1	O
(	O
PCD/DCoH	O
)	O
is	O
a	O
protein	O
that	O
has	O
a	O
dual	O
function	O
.	O
It	O
is	O
a	O
pterin	O
4alpha-carbinolamine	O
dehydratase	O
that	O
is	O
involved	O
in	O
the	O
regeneration	O
of	O
the	O
cofactor	O
tetrahydrobiopterin	O
during	O
the	O
phenylalanine	O
hydroxylase-	O
catalyzed	O
hydroxylation	O
of	O
phenylalanine	O
.	O
In	O
addition	O
,	O
it	O
is	O
the	O
dimerization	O
cofactor	O
of	O
HNF1	B-protein
that	O
is	O
able	O
to	O
activate	O
the	O
transcriptional	O
activity	O
of	O
HNF1	O
.	O
Deficiencies	O
in	O
the	O
gene	O
for	O
this	O
dual	O
functional	O
protein	O
result	O
in	O
hyperphenylalaninemia	O
.	O
Here	O
we	O
report	O
for	O
the	O
first	O
time	O
that	O
the	O
PCD/DCoH	O
mRNA	O
is	O
present	O
in	O
human	O
white	O
blood	O
cells	O
and	O
hair	O
follicles	O
.	O
Taking	O
advantage	O
of	O
this	O
finding	O
,	O
a	O
sensitive	O
,	O
rapid	O
and	O
convenient	O
method	O
for	O
screening	O
mutations	O
occurring	O
in	O
the	O
coding	O
region	O
of	O
this	O
gene	O
has	O
been	O
described	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
Biochemical	O
characterization	O
of	O
the	O
NF-Y	B-protein
transcription	I-protein
factor	I-protein
complex	I-protein
during	O
B	O
lymphocyte	O
development	O
.	O
The	O
transcription	B-protein
factor	I-protein
,	O
NF-Y	B-protein
,	O
plays	O
a	O
critical	O
role	O
in	O
tissue-specific	O
major	O
histocompatibility	O
complex	O
class	O
II	O
gene	O
transcription	O
.	O
In	O
this	O
report	O
the	O
biochemical	O
properties	O
of	O
the	O
heterotrimeric	O
NF-Y	B-protein
complex	I-protein
have	O
been	O
characterized	O
during	O
stage-specific	O
B-cell	O
development	O
,	O
and	O
in	O
several	O
class	O
II-	O
mutant	O
B-cell	O
lines	O
,	O
which	O
represent	O
distinct	O
bare	O
lymphocyte	O
syndrome	O
class	O
II	O
genetic	O
complementation	O
groups	O
.	O
The	O
NF-Y	B-protein
complex	I-protein
derived	O
from	O
class	O
II+	O
mature	O
B-cells	O
bound	O
with	O
high	O
affinity	O
to	O
anion	O
exchangers	O
,	O
and	O
eluted	O
as	O
an	O
intact	O
trimeric	O
complex	O
,	O
whereas	O
,	O
NF-Y	B-protein
derived	O
from	O
class	O
II-	O
plasma	O
B-cells	O
,	O
and	O
from	O
bare	O
lymphocyte	O
syndrome	O
group	O
II	O
cell	O
lines	O
,	O
RJ2.2.5	O
and	O
RM3	O
,	O
dissociated	O
into	O
discrete	O
NF-YA	O
and	O
NF-YB	B-protein
:	I-protein
C	I-protein
subunit	I-protein
fractions	I-protein
.	O
Recombination	O
of	O
the	O
MPC11	O
plasma	O
B-cell	O
derived	O
NF-Y	B-protein
A	I-protein
:	I-protein
B	I-protein
:	I-protein
C	I-protein
complex	I-protein
with	O
the	O
low	O
molecular	O
mass	O
protein	O
fraction	O
,	O
NF-Y-associated	B-protein
factors	I-protein
(	O
YAFs	O
)	O
,	O
derived	O
from	O
mature	O
A20	O
B-cell	O
nuclei	O
,	O
conferred	O
high	O
affinity	O
anion	O
exchange	O
binding	O
to	O
NF-Y	B-protein
as	O
an	O
intact	O
trimeric	O
complex	O
.	O
Recombination	O
of	O
the	O
native	O
NF-YA	O
:	O
B	O
:	O
C	O
complex	O
with	O
the	O
transcriptional	O
cofactor	O
,	O
PC4	B-protein
,	O
likewise	O
conferred	O
high	O
affinity	O
NF-Y	O
binding	O
to	O
anion	O
exchangers	O
,	O
and	O
stabilized	O
NF-Y	O
interaction	O
with	O
CCAAT-box	O
DNA	O
motifs	O
in	O
vitro	O
.	O
Interaction	O
